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Abstract
Background
The in-vivo assessment of cerebral amyloid load is taking a leading role in the early
differential diagnosis of neurodegenerative diseases. With the hopefully near introduction
of disease-modifying drugs, we expect a paradigm shift in the current diagnostic pathway
with an unprecedented surge in the request of exams and detailed analysis.
Up-to-date clinical practices can rely either on a rather invasive cerebro-spinal fluid assay
(CSF), or on a positron emission tomography (PET), where the availability of a small
number of radiotracers were validated to be effective proxy of brain amyloidosis.
With the increasing experience in amyloid-PET, the scientific community realized that
previous approaches to the analysis were not enough to capture the physiological variabil-
ity and serve as a reliable tool for both medical report and clinical research.
Materials
In this work I developed new approaches to amyloid-PET analysis. They were validated
and integrated in a common framework to be used in clinical practice. The integration
of these new approaches also allows a new measure paradigm (the rank), paving the way
for more robust evaluation of the PET scan.
Analyses were carried out on a total of ≈ 700 scans, coming from three dataset: the
Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Multicentric Pilot Dataset
(MPD) and a smaller single-center dataset which was used for side analyses.
These dataset are very diverse in terms of size (≈ 500, ≈ 150 and 40 respectively),
inclusion/exclusion criteria (research, trial based or naturalistic population), data quality
and number of participant centers. The tracer of choice was 18F-Florbetapir.
Methods
Two novel semi-quantification methods (ELBA and TDr) were developed, tested and
validated over the various dataset and versus the visual assessment. Test and validation
cases included: comparison with CSF values, coherence among quantifiers, clinical follow-
up, regional and longitudinal analysis.
A single quantifier (rank) was designed to summarize all results into a more robust index,
to be tested in clinical setting.
Results
We show that independent quantification methods can indeed be useful and complemen-
tary to the visual dichotomic assessment. The high internal coherence among methods
validated their applicability on a wide range of use cases, scanners and patient clinical
status.
These analyses are now running without human supervision and are currently under
testing in clinics thanks to a user-friendly web interface.
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Chapter 1
Research context
1.1 Scope and intent of this work
The latest research criteria for diagnosing Alzheimer’s Disease (AD) suggest that in-vivo
quantification of brain amyloid-β (Aβ) deposition using positron emission tomography
(PET) is emerging as a crucial tool in diagnosing or in excluding Alzheimer’s disease
(see Dubois et al. (2014), but also McKhann et al. (2011); Johnson et al. (2013a)) and is
likely to play a pivotal role in upcoming clinical trials of disease modifying agents (Fagan
et al., 2006; Klunk et al., 2004; Rowe et al., 2007). Biomarkers of cerebral β-amyloid
are increasingly used in clinical trials (Karran and Hardy, 2014; Blennow et al., 2013)
This stresses the need for reliable and available biomarkers of brain A β pathology. The
foreseeable increase in the use of this testing methodology, the sensitive nature of the
outcome for the patient prognosis and the availability of different radioligands pose new
challenges to clinicians.
Currently, human readers who want to acquire the necessary expertise are advised to
attend ligand-specific courses - often brought in by pharmaceutical companies - where
visual evaluation procedures tend to favour a dichotomic reading (positive/negative).
This approach is justified by the apparent scarcity of cases where the ligand uptake
distribution cannot be easily identified or where its spatial extent is limited. Indeed,
while most amyloid-PET images are rather easily evaluated by a trained eye, as amyloid-
PET becomes a widespread tool uncertain instances are going to be met more and more
frequently.
Because of the non trivial visual assessment in a non negligible number of cases, a more
sophisticated approach is required, which provides quantification (and rank) besides clas-
sification.
This work deals with proxy measures of brain amyloidosis derived from clinical-grade
positron emission tomography (PET) images. It involves significant methodological de-
velopments in order to deliver clinically usable indexes, with a significant impact on
Nuclear Medicine practices, training and assessment.
The shortcomings of current clinical practice when dealing with amyloid-PET images are
mainly due to the novelty of amyloidosis tracers and the uncertainties in the causative
models linking amyloid presence, neuroinflammation, neurodegeneration and symptoms.
This work examines these shortcomings and develops new approaches to overcome them.
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This leads to the development of new tools for quantification, their validation and their
implementation to enhance the clinical experience significantly.
The drastic reduction of the quantification uncertainty deriving from the conventional
calculation (i.e. SUVr) is fundamental not only to select and study atypical subjects
with borderline amyloid burden, but becomes necessary when considering longitudinal
measures to validate and monitor the effectiveness of future anti-amyloid drugs.
1.2 Brain amyloidosis
Amyloidosis is a general term that describes a wide spectrum of diseases characterized
by a deposit of amyloidogenic peptides in different organs. These peptides derive from
proteolysis of a transmembrane glycoprotein which is present in all the cells – although
predominantly in neurons – called amyloid precursor protein (APP).
The APP is processed by two secretase enzymes that act in sequence, leading to distin-
guished pathways (amyloidogenic and non-amyloidogenic) depending on which determines
the production of the Aβ peptide. APP may be initially cut by the α-secretase (non-
amyloidogenic pathway) or by the β-secretase (amyloidogenic pathway). Both secretases
generate a soluble fragment – the sAPPα and sAPPβ respectively – which is released
into the extracellular environment, and a C-terminal fragment which remains anchored
to the membrane (figure 1.1). The latter is used as a substrate by γ-secretase to generate
two other soluble fragments: the p3 peptide, that corresponds to the region 17-40/42 of
Aβ sequence in the non-amyloidogenic pathway; and a Aβ fragment consisting of 40/42
amino acids, that comes from the amyloidogenic pathway (γ site) and has fibrillogenic
characteristics.
Figure 1.1: Formation of the peptide β amy-
loid. The γ-secretase in the amyloidogenic
pathway can cut the βAPP CTF in two dif-
ferent points of its sequence: γ-40 and γ-42,
and generates two different amyloid peptides:
Aβ1-40 and Aβ1-42, which are able to be
shaped into β-sheets and aggregate into fib-
rils.
As there are physiological mechanisms for
the production of Aβ, there are clearance
pathways. Two main mechanisms have
been identified:
• the transport of Aβ (predominantly
in the form Aβ1-40) across the blood
brain barrier into the circulation
(Zlokovic, 2004)
• the degradation of Aβ (predomi-
nantly in the form Aβ1-42) by means
of peptidase (Gue´nette, 2003; Tanzi
et al., 2004) such as NEP (neutral
endopeptidase) and IDE (insulin de-
grading enzyme).
The first mechanism involves the transport
mechanism in the blood which is mainly
mediated by LRP-1 receptor (LDL recep-
tor related protein-1) in the cerebral mi-
crovascular endothelium.
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Figure 1.2: Aβ toxicity mechanisms.
The main forms of Aβ peptides consist of 40 or 42 amino acids (Aβ1-40 Aβ1 -42), distin-
guishable for the different COOH terminal.
The longest form (Aβ1-42) is equipped with two additional hydrophobic amino acid
residues; it is able to aggregate more rapidly and to form fibrils, therefore it is the peptide
that is initially deposited for the formation of plaques (Glabe, 2001).
The Aβ in the brain tissue exists in various states of aggregation as monomers, dimers
and oligomers of high molecular weight (Fig. 1.3); the aggregation of oligomers eventually
generates proto-fibrils and then the fibrils (Klein et al., 2004). That said, only the fibrils
are going to form plaques.
The Aβ peptides are neurotoxic. Early in vitro studies compared the effect of the fibrils
and monomers, finding that the latter gave no toxicity effect (Lorenzo and Yankner, 1994).
Therefore the main object of the studies is Aβ in the fibrillar form, which is considered
responsible for the cytotoxic effect observed also in-vivo conditions.
According to the amyloid cascade hypothesis, the accumulation of fibrillar Aβ in the form
of plaques damages neurons through two different mechanisms (Fig 1.2):
• a direct mechanism, where Aβ interacts with components of the cell membrane and
directly damages neurons and / or increases the susceptibility of neurons to a variety
of damage factors such as excitotoxicity, hypoglycemia or peroxidative damage (Koh
et al., 1990)
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• an indirect mechanism, Aβ damages neurons through the activation of the microglia
and astrocytes to produce toxic and inflammatory mediators, such as nitric oxide
(NO), cytokines and reactive oxygen intermediates (Meda et al., 1995; Bianca et al.,
1999), that cause neuronal death by apoptosis or necrosis.
Figure 1.3: Overview of the Aβ production
and aggregation.
Amyloid deposit in the central nervous sys-
tem represents the most frequent form of
amyloidosis in humans. When these de-
posits are initially localized in the walls of
cerebral blood vessels the most common
clinical manifestation is the stroke; when
deposits extend through selected parenchy-
mal areas, particularly the limbic system,
these are associated with neurodegenera-
tion leading to dementia.
1.3 Amyloid-related
pathologies
Amyloid-β deposit is characteristic of some
neurodegenerative diseases associated with
dementia: the Alzheimer’s disease (AD)
and the Lewy bodies family (including de-
mentia with Lewy bodies and Parkinson’s
disease).
Aβ is also associated with other disease
processes that affect brain function such as
cerebral amyloid angiopathy (CAA), brain
trauma including traumatic brain injury (TBI) and chronic traumatic encephalopathy
(CTE), Down’s syndrome (DS) and meningiomas.
While amyloid accumulation can occur in the body too – for example systemic amyloidosis
involving the heart (Ikonomovic et al., 2008) – its presence in the CNS is the most studied
case as it is linked to AD.
Alzheimer’s disease is a complex, irreversible neurodegenerative disease, characterized by
an initial general cognitive decline and marked memory loss progressing to dementia and
severe impairment of daily life functions. Typical presentations of the disease lead to the
death of the patient after 7–10 years from diagnosis.
AD is a high-prevalence disease in the elderly population (' 30% for ages > 75 years)
with an estimated 14 million patients in Europe and the United States. The progressive
nature of this particular neurodegenerative disorder is linked to the synaptic and neuronal
damage in cortical areas devoted to memory (starting from the medial temporal lobe) and
then affecting broader areas in the frontal and parietal lobes. Macroscopically, early stages
are characterized by synaptic loss and neuronal damage, accompanied by a reactive gliosis
and the deposition of neurofibrillary tangles (NFTs, consisting of hyperphosphorylated
tau proteins P-tau) and Aβ plaques, while advanced stages are characterized by severe
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neuronal loss leading to cortical and sub-cortical atrophy. To date, the available genetic,
pathological and biochemical data support the thesis that the alteration of the balance
between amyloid production and clearance is the main input in the cascade of events that
leads to neurodegeneration and dementia.
1.4 Clinical criteria and diagnosis
The clinical diagnosis of AD has been linked to the presence of dementia for many years.
The first criteria were introduced in 1984 by the National Institute of Neurological and
Communicative Disorders and Stroke’s Alzheimer’s Disease and Related Disorders Asso-
ciation (ADRDA-NINCDS). They were still focused on the clinical presentation, saying
that (1) diagnosis of AD could only be considered as likely until confirmed by autopsy;
and (2) the clinical diagnosis could only be confirmed when the disease was at an advanced
enough stage to cause significant functional disability.
In 1995 Braak and Braak worked out the staging of AD pathology severity based on
neurofibrillary changes, that is by identifying six stages of disease progression which can
be distinguished on the location and concentration of NFT (fig 1.4, Braak and Braak
(1995)).
Figure 1.4: Braak stages.
The extensive research carried on over the
next several years in the field of neuroimag-
ing and biochemistry have led to the formu-
lation of a new clinical entity: the mild cog-
nitive impairment or MCI. MCI is a syn-
dromic condition which identifies a popu-
lation of patients with objective (i.e. con-
firmed by suitable neuropsychological ex-
amination) cognitive impairment in one or
more cognitive spheres, while still being
unimpaired in everyday life. Follow-up
studies of this group have shown that MCI
have a high risk of developing AD, with ap-
proximately 50% of them converting within
2-5 years after diagnosis. Other risk fac-
tors include genetic (ApoE  genotype),
lifestyle, history of psychiatric conditions
and education, possibly modulated by sys-
temic co-morbidities such as diabetes and
vascular diseases.
In 2007, the International Working Group
(IWG) for New Research Criteria for the
diagnosis of AD and subsequently the Na-
tional Institute on Aging-Alzheimer’s Association (NIA-AA), have revisited the NINCDS-
ADRDA guidelines and delivered new criteria introducing the biomarker concept, by
which the diagnosis of AD is related to the presence of biological markers; thus the di-
agnosis started the transition from a clinical-pathological entity to a clinical-biological
one.
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These criteria required that AD can be recognized in vivo and regardless of the dementia
symptoms if the presence of at least two essential criteria can be objectively measured.
The first requirement is a core clinical phenotype that requires evidence of significant
memory impairment, associated with a progressive worsening of the performance. In
addition, the diagnosis of probable AD would require support features represented by
objective evidence of alteration in one or more of the following biomarkers:
• presence of atrophy of the medial temporal lobe measured with Magnetic Resonance
Imaging (MRI)
• anomalous protein concentration (Aβ42) in the cerebro-spinal fluid (CSF)
• impaired glucose metabolism in the brain, measured by 18F-fluorodesoxyglucose
Positron Emission Tomography (FDG-PET).
The introduction of biomarkers as a support feature (although still not mandatory for the
diagnosis) was the most important innovation introduced by the criteria of 2007. This
radical change allowed the identification of the so-called prodromal AD, that is a condition
at risk of AD where at least one biomarker shows typical alteration.
In 2010, the same group of authors published a second paper, redefining the lexicon of
Alzheimer’s pathology and disease. AD now becomes a life-long process, a continuum
ranging from an (asymptomatic) pre-clinical stage, to mild cognitive impairment and –
only in the end – to dementia. The Braak stages (transentorhinal I, II; limbic III, IV and
neocortical V, VI) are then linked with pre-clinical – or asymptomatic – AD; prodromal
AD, with symptoms or signs of cognitive impairment (one or more altered biomarkers);
and symptomatic AD.
In 2011, experts from the National Institute of Aging (NIA) along with those of the
Alzheimer’s Association (AA) issued new clinical criteria (NIA-AA) in which various
states of the pathology are defined, with and without the biomarker support. The NIA-AA
criteria define three frameworks: asymptomatic (preclinical AD), pre-dementia (prodro-
mal AD - MCI due to dementia), and dementia (due to AD). These criteria also introduce
three different states for each of the three frameworks. The asymptomatic or pre-clinical
stage was divided in
• Stage I: asymptomatic cerebral amyloidosis characterized by the positivity of amy-
loidosis biomarkers
• Stage II: confirmed amyloidosis accompanied by neurodegeneration markers, al-
though still without significant cognitive symptoms
• Stage III: similar to stage II but with signs or symptoms, although still insufficient
to diagnose the state of MCI
Both IWG criteria and NIA-AA recognize that the AD starts before symptoms occur, but
the NIA-AA identify patients with evidence of Aβ accumulation as asymptomatic AD,
whereas in the IWG criteria the amyloid deposit is only identified as a risk factor.
For the stages of pre-dementia and dementia, NIA-AA criteria recognize three levels of
probability (high, intermediate or unlikely) that the disease is due to AD based on the
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information of biomarkers, which now increase the confidence level of diagnosis and are
no longer a criterion of diagnosis by themselves.
In a recent position paper, the International Working Group (IWG) (Dubois et al., 2014)
presented a review of the diagnostic criteria for Alzheimer’s disease. Based on an extensive
review of the recent literature (from 2007 to January 2013), the authors proposed a
diagnostic algorithm that allows the application of the same criteria in different stages
of the disease, further strengthening the understanding of Alzheimer’s disease as dual
clinical-biological entity.
These reviewed criteria also deals with typical, atypical and mixed AD. They require
that in-vivo evidence of Alzheimer’s-like pathology be demonstrated by positivity of at
least one biomarker such as: reduction of the concentration of Aβ1−42 in the CS together
with increased concentration of phosphorylated-τ (alternatively the increased uptake of
radiopharmaceuticals for amyloid at PET); the presence of autosomal dominant mutation
typical of AD (in PSEN1, PSEN2 or APP genes).
An important departure from previous criteria is the appearance of the distinction between
patho-physiological biomarkers – which are necessary for the diagnosis – and topograph-
ical or progression biomarkers that are no longer included in the diagnostic process but,
albeit having a lower specificity for Alzheimer’s Disease, are closely related to the clinical
manifestations and its severity.
The presence of pathological amyloid load is not in and of itself diagnostic of AD, but
the absence of amyloid in a patient who is having symptoms of either mild cognitive
impairment or early dementia excludes AD as the basis of that dementia. While it doesn’t
give the precise alternative diagnosis, it does tell that AD in that specific clinical context
– that otherwise fits with AD – is quite unlikely.
Further studies indicated that the relationship between AD, amyloid burden, neurodegen-
eration and NFT can be rather complicated. In most cases, AD-related symptoms follow
a significant brain amyloid burden, but there are also a number of subjects in which
neurodegeneration (and symptoms) is present without brain amyloidosis. These subjects
are tagged Suspected non-Alzheimer patho-physiology (SNAP). In addition, there are also
subjects showing NFT indistinguishable from those observed in AD, but still without brain
amyloidosis; these are tagged Primary age-related tauopathy (PART) (Montine et al.,
2011; Jack, 2014) Autoptic studies have indeed found correlation between neurofibrillary-
mediated neurodegeneration and cognitive decline but not between neurodegeneration
and amyloid plaques (Crary et al., 2014).
Chapter 2
PET fundamentals
Positron emission tomography is an imaging technique used in nuclear medicine that al-
lows non-invasive visualization and quantification of biological and physiological processes.
This technique provides three-dimensional images of the anatomical district under exam-
ination by exploiting the decay processes of radioactive isotopes, which were previously
introduced into the patient’s bloodstream by injection of a radiopharmaceutical (Bailey
et al., 2005).
This methodology is used extensively both in clinical oncology (to grade tumors and for
the research of metastases), and in neurology (for the study and clinical evaluation of
various neurodegenerative pathologies) (Catafau and Bullich, 2015).
2.1 Physics principles
PET uses the decay processes of radioactive isotopes used to mark molecules called tracers
(or radiopharmaceuticals) that are administered intravenously. PET tracers are marked
with radioisotopes that decay β+ (that is emitting a positron e+ and a neutrino νe).
These molecules are engineered to take part in a specific biological process related to the
pathology under consideration. After the tracer is administered, the patient is placed in
the scanner for the acquisition.
In this framework, the measure consists in detecting the number of counts in a given
volume, where the measure timings are short when compared to the half life of the ra-
dioisotope, and long with respect to the biochemistry kinetics that guide the tracer spread
into the anatomical region under investigation.
The radioisotope marking the tracer decays through the emission of a positron (e+) which,
in organic tissues, has a mean free path of 1 ∼ 2mm. The positron then annihilates with
an electron and two collinear photons of 0, 511MeV are then emitted (figure 2.1).
As the photon direction is random, one needs to detect the coincidence of coplanar events.
A series of scintillators fashioned in a circular array around a central axis detects a signal
only when two collinear events are detected within a time-difference of 10 − 20ns, thus
revealing the emission line of sight. Significant post processing of this raw signal is needed
though, to retrieve the emitter position.
Typical radioisotopes are 18F and 11C, due to the fact that they can be easily produced
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in cyclotrons and that their half-life is rather short: ∼ 110 min and ∼ 20 min respectively
(thus avoiding enduring radiation hazard for patients).
Figure 2.1: Decay of the radioisotope 18F
and annihilation of the positron with an elec-
tron, resulting in the emission of two γ pho-
tons.
The most common radioisotope is 18F ,
which decays as follows:
18
8 F → 189 O + e+ + νe (2.1)
2.2 Detection
The acquisition system in PET is a scanner
consisting of a ring of scintillators coupled
to photomultipliers. The patient is lying on
a support which can slide within the ring.
The detection is obtained by means of scin-
tillators, that convert high energy pho-
tons – generated by the annihilation of the
positron – into photons of relatively low en-
ergy (in the visible spectrum). These pho-
tons reach the photocathode of the photo-
multipliers, which converts the light signal
into an electrical signal.
To avoid counting photons not due to
an annihilation event, it is necessary to
energy-select the events. The energy range
(or window) is usually chosen as 350− 650 keV (Saha, 2016).
Signal is then detected through a coincidence filter, which selects simultaneous events
(∆t < 10 − 20ns). When two photons are detected both within the time window and
within the energy window, they are registered as a coincident count, which occurred along
an imaginary line connecting the two scintillators that recorded the event and called the
line of response (LOR).
The three-dimensional image is reconstructed by joining an ordered sequence of two-
dimensional images obtained by sliding the support on which the patient is positioned.
These two-dimensional images are obtained through complex reconstruction algorithms
that use the profiles of the counts detected on each acquisition plane. The final im-
age consists of a three-dimensional matrix with scalar values, whose element intensity is
proportional to the concentration of the radiopharmaceutical in the tissue.
The spatial resolution of PET images is generally 2− 3mm and depends on many factors
such as the mean free path of the positron, the structure of the detector and the size and
shape of the scintillators (Bailey et al., 2005).
2.2.1 Detection issues
The mass of the parent nuclide in the decay exceeds the sum of the masses of the decay
products, so the difference in mass is converted into energy and is available to the gener-
10 Chapter 2. PET fundamentals
Figure 2.2: Pictorial representation of a typical PET detector, consisting of a ring of
scintillators coupled to photomultipliers and a processing unit to retrieve the emitter
position.
ated particles. Most of this energy is transferred as kinetic energy to the positron and to
the neutrino, or converted into photons, and only a small part is transferred to the child
nucleus (still as kinetic energy).
The positron resulting from the decay will interact with the atoms of the tissue, losing its
kinetic energy and finally annihilating with an electron. The maximum traveled distance
depends on the initial kinetic energy of the positron, and it is of the order of 2.4mm for
18F (Cherry et al., 2004).
If the positron has not exhausted its kinetic energy before annihilation there is an energy
excess, which – in addition to the fact that the electrons of the tissue are also moving
– is manifested as a non-collinearity of the two photons produced by the annihilation.
This non-collinearity is of the order of some fraction of a degree, which, in a typical PET
scanner, amounts to an uncertainty in the annihilation cohordinates of 2− 3mm.
After the annihilation event, the photons will travel in the patient’s tissues in opposite
directions; in this phase, different types of interaction occur between the photon and
the medium, which attenuate or block the intensity. The modulation property of the
medium depends on its characteristics (such as the density), and is described by a linear
attenuation coefficient µ. Mathematically, the fraction of photons that crosses a thickness
x of matter with attenuation coefficient µ is expressed by the following relation:
Γ = e−µx
which extends naturally to a sequence of materials with thickness xi and coefficient µi as:
Γ = e−
∑
i µi xi
The general formula for a detector measuring N0 events from a radioactive source without
attenuation (for example in air where µ ≈ 0), in the presence of matter becomes:
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Figure 2.3: Types of coincidences in a PET scanner (courtesy of (Ha¨ggstro¨m, 2014))
N = N0 e
− ∫ d0 µ(x)x dx
where mu(x) is the linear attenuation coefficient expressed as a function of the coordinate
for the different types of tissues and d represents the total distance between the source
and the detector.
The attenuation phenomenon in human tissues can be rather significant, so that it is
necessary to know the magnitude of this effect to obtain the real distribution of the
tracer within the patient. In modern scanners, PET is combined with computerized
tomography (CT), which delivers morphological and tissue properties information. The
CT is converted into an attenuation map and used to correct the intensities in the image
(Lonsdale and Beyer, 2010; Bailey et al., 2005).
While the attenuation coefficient is a function of the tissue alone, the reduction of the
photon count rate corresponding to a specific local distribution is also a function of the
LOR on which it is detected. Ideally, the only events that should be recorded are those
associated with the actual annihilation of positrons, called true coincidence; however, a
series of fringe events which satisfy the coincidence detection criteria are still considered
as annihilation events, resulting in noise and degradation of spatial resolution.
Most of the spurious coincidence events are classifiable in the three types (figure 2.3)
• True coincidence: associated with the detection of a pair of photons emitted
by the annihilation event. The two photons are revealed within the temporal and
spatial coincidence window, that is, between an opposed pair of scintillators.
• Scattered coincidence: occurs when one or both photons undergo Compton scat-
tering. The Compton interaction causes both energy loss and change of direction,
resulting in an incorrect location of annihilation, and ultimately in image degrada-
tion and a reduction in contrast.
• Random coincidence: when photons associated with two distinct annihilations
are seen by the detection system as coming from a common annihilation event.
Random coincidences are sources of noise and are generally proportional to the
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square of the activity in the field of view (FOV), as well proportional to the time
and energy window.
Acquisitions with PET tomographs in the presence of high counts rate are strongly
degraded, so it is necessary to apply corrections for this type of error. A random
event evaluation method is known as the coincidence cancellation method: the tem-
poral coincidence window is not opened when the first photon hits the detector, but
with a special delay to avoid any real coincidence. The ratio between the number of
coincidences with and without an applied delay provides the relationship between
real coincidences and random coincidences (Bailey et al., 2005; Saha, 2016).
Figure 2.4: The image space (xy) is repre-
sented in sinogram space (rθ). A group of
LORs constitute a projection profile, corre-
sponding to a column in the synogram. A
point in the image space corresponds to a
curve in the space of the sinogram, while a
point in the space of the sinogram is a LOR
in the image space (courtesy of Ha¨ggstro¨m
(2014)).
A considerable improvement over the sim-
ple LOR reconstruction is the ability of lo-
cating the annihilation event along it; this
is achieved thanks to the time of flight
(TOF) technique.
Thanks to the recent introduction of new
scintillator crystals and electronics with
better temporal resolution, it is now possi-
ble to obtain information on approximate
position of the annihilation event along the
LOR by measuring the small time differ-
ence in the detection of the two photons.
For an annihilation event placed at ∆x
from the center of the FOV, the ∆t be-
tween the two detections will be:
∆t = 2
∆x
c
The time difference is really tiny: for a
spatial offset of 9 cm the required tem-
poral resolution is 600 ps. TOF informa-
tion considerably improves image quality,
contrast and signal-to-noise ratio (Vanden-
berghe et al., 2016).
2.3 Image reconstruction
PET raw data are stored into two-dimensional matrices called the sinograms (fig 2.4).
Each pair of detectors records the line or projection integral, i.e. the sum of the co-
incident events along the respective LOR, which is identifiable by two parameters: the
perpendicular distance from the center of the FOV (r) and an angle (θ).
The goal of the reconstruction phase is to recover the radiopharmaceutical distribution
starting from the sinogram; that is taking the synogram data and delivering a three-
dimensional matrix whose element (called voxel 1) is located in the appropriate anatomical
1A voxel (volumetric image element) is a volume element representing an intensity in a three-
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position, and whose value gives information about the radiopharmaceutical uptake.
There are two main reconstruction methods: analytical algorithms, in which the math-
ematical model is analytically inverted (such as the Filtered backprojection, FBP), and
iterative algorithms (such as the Ordered Subset Expectation Maximization, OSEM), in
which the tomographic image is reconstructed using iterative statistical methods (Bai-
ley et al., 2005; Hudson and Larkin, 1994). Given the proven superior performance of
iterative methods, we shall only consider these for a brief introduction.
2.3.1 Iterative approach
Iterative methods estimate a series of tentative radioactivity distributions and compares
the respective projections with those actually acquired, refining the former at each iter-
ation until correspondence is satisfactory (Madsen, 2005). While computationally more
expensive, it allows to modulate and account for the statistical fluctuations associated
with noise, both on the reconstructed images and on the raw data side (Herman, 2009).
Figure 2.5: Pictorial representation of
eq. 2.3.1 (courtesy of (Alessio and Kinahan,
2006))
In addition, estimation models can be com-
plemented with a-priori information, such
as the CT acquisition, which enhance the
spatial resolution and greatly improves the
reconstruction process.
Iterative methods employ two algorithms:
one evaluates the projections of the esti-
mated object versus the acquired one, and
another that makes the new estimate based
on these differences. The goal is to find f¯
as solution of the equation
~p = H · ~f + ~n (2.2)
where ~p is the vector of counts represented
as a sinogram, H is a coefficient matrix, ~f
is the unknown image vector and ~n is the
noise.
An optimized solution method for eq. 2.2
is known as maximum likelihood expectation maximization (MLEM) (Dempster et al.,
1977; Bruyant, 2002). This method exploits the fact that the processes of radioactive
disintegration are described by the Poisson distribution (Hudson and Larkin, 1994). The
MLEM algorithm finds the best estimate of the counts for each element of the image
(henceforth labeled as fk). This operation is performed by looking for, and mapping the
average number of disintegrations that can most likely determine the counts acquired onto
the projections (pi).
Iterative methods consist of five basic steps (Alessio and Kinahan, 2006):
• the image model, which usually consists in the discretization of the space domain
in N pixel voxel depending on the approach (2D or 3D);
dimensional space, similar to the pixel which represents a image element in a two-dimensional space.
14 Chapter 2. PET fundamentals
• the system model H, that links the tentative image with the projections; the Hik el-
ement of the system model is characteristic of the imaging system and represents the
probability that an output from the volume element k is revealed in the projection
i;
• the statistical model, which describes the relationship linking the measurements to
their expected values. Most approaches consider photon detections to follow the
Poisson statistics;
• the metric, that is the measure used to define the “best” image
• the maximum likelihood estimator, which optimizes the likelihood function L over
the parameters to deliver the best estimate of the image at each iteration.
Equation 2.2 is expanded – neglecting noise – to write p¯i explicitly as the average counts
on the i− th projection and fk as the activity of element k (see figure 2.5)
p¯i =
K∑
k=1
Hik fk
Assuming every pi is an independent Poisson variable, the likelihood (L) to observe ~p
when the emission map is ~f is written as the product of the probabilities associated with
each bin of the synogram as:
L(P = ~p|~f) =
M∏
i=1
e−p¯i
p¯i
pi
pi!
(2.3)
where M is the total number of projections.
Maximum likelihood estimators are advantageous because they offer unbiased, minimum
variance estimates as the number of measurements increases towards infinity. This means
that as the number of measurements or projections becomes large the expected value of
the image estimate approaches the true image. Due to the inherent noise in emission
photon counting, methods often choose to allow some bias in the reconstructed image in
return for reduced noise levels. This bias is introduced in the form of spatial smoothing
effectively adding error to the image mean values while reducing overall noise levels. This
smoothing is performed either implicitly by stopping the algorithm before reaching the
ML solution or explicitly through some smoothing operation.
The maximum likelihood solution of 2.3 gives the iterative equation:
fˆj
(m+1)
=
fˆj
(m)
n∑
i=1
Hij

n∑
i=1
Hij
pi
K∑
k=1
Hik fˆk
(m)

where fˆj
(m+1)
is the m+1 iteration estimate of voxel j in iteration m.
The MLEM algorithm usually requires from 20 to 50 iterations to reach an acceptable
solution, starting from an initial estimate fˆj
(0)
(which is often a constant image).
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Since MLEM requires a projection and a rear projection at each iteration, the total
processing time is considerably greater than that required by any analytical algorithm.
To improve on this, current standards employ the ordered-subset version (OSEM) of the
MLEM. This slight modification of ML-EM uses subsets of the entire data set (for instance
by dividing the projections into sets with different views, or azimuthal angles) to ensure
a rapid convergence of the algorithm (Hudson and Larkin, 1994).
The OSEM methods are a family of algorithms where bias, a-priori knowledge, system-
specific issues and statistical models can vary quite a bit, so that not all algorithms are
alike in terms of performance and image quality.
2.3.2 The point spread function
Many common figures of merit are used to describe the spatial resolution of reconstruction
methods. Resolution is loosely defined as the level of reproduction of spatial detail in the
imaging system.
This is often expressed though the point spread function (PSF). Imagine a single point
source is placed in the system and reconstructed into an image: the reconstructed image
is a spread out version of the point. In PET, the PSF is frequently characterized by the
transaxial and axial Full Width at Half Maximum (FWHM) term, which describes the
width at half of the maximum value of the PSF of a Gaussian shaped function fitted to
the PSF (in the transaxial or axial direction). This term captures some of the behavior
of the resolution of the method, but does not do a good job describing the lower values
of the PSF, considering the Gaussian function has very long tails. Other descriptive
resolution values include the Full Width at Tenth Maximum (FWTM, computed similarly
as FWHM) and properties of the modulation transfer function (Fourier transform of PSF).
Considering that the smoothing required to reduce the variance in images leads to de-
graded resolution, the bias-variance trade-off also translates to a inherent resolution-
variance trade-off. Therefore, it is not adequate to simply state method A yields better
resolution than method B, but must be shown that at an equal variance level, method A
has better resolution than method B. While it is advantageous to have an imaging system
with as low a FWHM as possible, this often affects the system sensitivity (count rate).
The PSF can also be derived analytically (Schmitt et al., 1988), with a Monte-Carlo
simulation (Alessio et al., 2006) or by direct measurement (Panin et al., 2006). The
inclusion of the PSF in the reconstruction methods improves the spatial resolution as well
as the contrast (Panin et al., 2006).
2.3.3 Partial volume effect
The PSF concept is closely tied to another PET image issue: the partial volume(PV)
effect (figure 2.6). PV refers to the fact that a pixel includes a mixture of signals coming
from different sources. Two phenomena cause this mixture: the limited spatial resolution
of the imaging system and the image sampling. Owing to the image blur introduced by
limited spatial resolution, the signal coming from a point source will be detected not only
in one pixel, but also in neighboring pixels. When considering a functional structure of
interest, part of the activity from the structure will thus also be detected outside of a
VOI drawn around the structure, an effect that is called spill-out. Conversely, activity
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Figure 2.6: Partial volume effect due to the spatial resolution of the imaging system.
(a) (b)
Figure 2.7: (a) Illustration of spill-out and spill-in PV effects. Spill-out results in esti-
mating reduced activity in a region that has higher activity than its surroundings; spill-in
results in overestimating the activity in a region that has lower activity than its surround-
ings. (b) This effect has also a significant impact on the contrast.
from structures close to the structure of interest will spill-in to the structure of interest.
Therefore, if one considers only the most intense pixel to estimate the source activity, this
activity will be underestimated but this underestimation might be partially compensated
for by spill-in. Activity in neighboring pixels will be overestimated. Overall, PV thus
introduces quantitative biases. (Matsubara et al., 2016). Both effects are shown in figure
2.7.
2.3.4 Image quality
The definition of image quality in nuclear medicine (and hence that of ‘best’ image) is
still rather open. An objective comparison of image quality is often difficult and can only
be performed in the context of a specific application, or task. The working definition is
that image quality must be assessed on the basis of average performance of some task of
interest by some observer or decision maker (Barrett, 1990).
Two of the major imaging task categories are classification tasks and estimation tasks.
Classification tasks categorize the image or features in the image into one or more classes.
A common classification task is detection (a binary classification task). Some other exam-
ples of classification tasks include signal detection, image segmentation and diagnosis. On
the other hand, estimation tasks seek numerical parameters from an imaging system such
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as the quantitation of physiological parameters or the estimation of features for pattern
recognition. Specific examples of estimation tasks include a cardiac ejection fraction or
the value of tracer flux in a tissue compartment model.
Perhaps the most common task in nuclear medical applications is the detection of tumors.
Since a physician assesses images for this classification task, the best method for evaluating
reconstruction methods for detection is a human-observer study. Unfortunately, thorough
human- observer studies are time consuming and often impractical because they require
the evaluation of numerous reconstructed images and ideally numerous trained observers.
The theoretical approach to image quality shall not be investigated in this work. Its
consequences shall be seldom looked into, although quality assessment will always be a
tangible issue and sometimes a real nuisance for the quantification tasks. The practical
definition of a “good” PET scan – and the minimal hardware and software requirements
to achieve it – is outside the scope of this work and is currently debated in Imaging Study
Groups of Nuclear Medicine Societies.
Chapter 3
Amyloid PET
The first amyloid-specific PET ligand was developed by Mathis and Klunk at Pittsburg
University. It was derived by a modification of tioflavin-T, a fluorescent colorant used in
neuropathology to mark amyloid plaques in brain tissue. The modified molecule (Pitts-
burgh Compound B, PIB) was marked with 11C, and the first human studies have been
carried out since 2002 in collaboration with the Uppsala University (Sweden). PIB has
since been comprehensively studied at many institutions around the world that have com-
pared the amount of amyloid in the brain.
Numerous studies are now available which look at different aspects of 11C-PIB PET: from
tracer build-up as a function of age to the comparison across different disease states. They
have also investigated patients who were amyloid positive and followed them over time
to see whether they develop typical clinical patterns of Alzheimers disease. So amyloid
imaging has been well established as a robust biomarker of the presence of abnormal
amyloid deposition in the brain, which is one of the key pathologic features of AD.
Based on the results with PIB, there was a great deal of interest in development of PET
agents labeled with 18F. It first began with Avid radiopharmaceuticals (Eli Lilly), which
received U.S. Food and Drug Administration (FDA) approval in 2012 for the first PET
imaging agent, Amyvid. There have been two subsequent approvals: GEs Vizamyl, and
Piramals Neuraceq.
Because of considerable clinical interest in amyloid imaging, the Society of Nuclear
Medicine and Molecular Imaging and the Alzheimers Association developed appropriate
use criteria with well-defined indications for clearing up confusing clinical situations
and aiding in patient management. The criteria also provided guidance on when use of
amyloid imaging was inappropriate.
3.1 Radiotracers
The amyloid-specific radiopharmaceutical must possess some key properties: they must
be a small lipophilic, non-toxic molecule, with a high affinity binding, specificity and
selectivity for Aβ and reactive to relatively long-lived radioisotopes like 18F or 11C. In
addition, no radio-labelled metabolites that bind to the brain should be formed.
The first and most studied molecule is the Pittsburgh Compound, a derived compound
of the tioflavine-T. It is a small, neutral and quite lipophilic molecule with formula 2 –(4
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Figure 3.1: Fluorinated radiotracers
–[11C] –(methylamino)phenyl) benzo[d]thiazol –6 –ol. Its fluorinated analog is the 2 -(3
-[18F] -fluoro -4 -(methylamino)phenyl)benzo[d]thiazol -6 -ol, known with the name of
18F–Flutemetamol. Finally there are two more compounds derived from the Polietilen
Glicole Stilbene: (E) -4 -(2 -(6 -(2 -(2 -(2 -18F -fluoroethoxy) ethoxy) ethoxy) pyridine -3
-yl) vinyl) -N -methylbenzenamine, 18F-Florbetapir and 18F-Florbetaben (figure 3.1).
Overall, binding affinity and lipophilicity are the most important properties for in vivo
tracing of neuroimaging. Although lipophilicity is needed for the tracer to cross the blood-
brain barrier (BBB), if the radiopharmaceutical is too lipophilic it may deliver signal (i.e.,
binding) in sites other than those containing Aβ.
Preclinical and autoptic studies have shown that the cerebral cortical uptake of in-vivo
tracers is correlated with the load of neuritic plaques observed post-mortem in the same
regions. Tracers rapidly enter the brain through passive diffusion of the BBB and the
fraction reaching the site of interest is very high, mostly depending on the regional blood
flow. An important source of variability in the extent of the amyloid load stained by the
different tracers derives from the time the different tracers spend in the white matter and
the absorption in the gray matter. While the high affinity binding to amyloid fibrils results
in a much slower clearance from the amyloid plaques in the gray substance, clearance from
the white substance depends on the degree to which non-specific low-affinity links occur;
for example, more lipophilic tracers may have a high distribution volume in the lipid-rich
white substance.
3.2 Appropriate clinical use
Several Working Groups worldwide considered a range of clinical scenarios in which amy-
loid PET should be recommended. The guidelines are based on peer-reviewed, published
literature, to ascertain available evidence relevant to the recommendations.
Although empirical evidence of impact on clinical outcomes is not yet available, a set of
specific recommended use criteria were agreed to define the types of patients and clinical
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circumstances in which amyloid PET could (and should not) be used.
As both dementia care and amyloid-PET technology are in active development, recom-
mendations are subject of periodic reassessment. The reader is referred to (Johnson et al.,
2013a) and (Guerra et al., 2015) for more insight into the criteria.
To date, a succint review of the guidelines implies that amyloid-PET is appropriate when
these conditions are satisfied:
• a cognitive complaint with objectively confirmed impairment is present;
• Alzheimers disease as a possible diagnosis, but when the diagnosis is uncertain after
a comprehensive evaluation by a dementia expert;
• when knowledge of the presence or absence of amyloid-beta pathology is expected
to increase diagnostic certainty and alter management.
Typical patients are those:
• with persistent or progressive unexplained mild cognitive impairment;
• satisfying core clinical criteria for possible Alzheimers disease because of unclear
clinical presentation, either atypical clinical course or etiologically mixed presenta-
tion;
• with progressive dementia and atypically early age of onset (usually defined as 65
years or less in age).
Conversely, amyloid imaging is inappropriate in the following situations:
• patients with core clinical criteria for probable Alzheimers disease with typical age
of onset;
• to determine dementia severity;
• as surrogate of genotyping for suspected autosomal mutation carriers;
• in asymptomatic individuals;
• non-medical usage (e.g. legal, insurance coverage, or employment screening);
The natural extension of the appropriateness guidelines consists in contextualizing the
amyloid PET into the general diagnostic tree and the decision-making process. The
guidelines therefore should be seen outside the nuclear medicine setting and should span
a far broader scope involving neurologists, dementia experts and neurophychologists. For
instance, dementia experts – and in general the clinical team that deals with these patients
– should provide proper documentation to demonstrate the medical necessity of an amyloid
PET scan.
In addition, all pertinent clinical expertises should help in identifying a specific subset of
individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate.
Finally, it is the greater health policy infrastructure (in charge of developing educational
programs) who must increase the awareness on the amyloid PET appropriate use, and
who is in charge of providing instructions on how this test should be used in the clinical
decision-making process.
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Tracer Dose Time after injection (min) Acquisition (min)
18F-Florbetapir 370 MBq (10 mCi) 30–50 10
18F-Flutemetamol 185 MBq (5 mCi) 90 20
18F-Florbetaben 300 MBq (8 mCi) 90 20
Table 3.1: Injection parameters.
3.3 Evaluation in clinics
The administration of the tracer and the reading of the PET scans must be performed
by a trained nuclear medicine doctor, as requested and recommended by the respective
companies (table 3.1). Criteria for interpretation may differ among the available tracers
and readers should apply the specific FDA and EMA recommendations for a given ligand.
Although the assessment should be given independently from previous neuroimaging and
clinical data, in general one should consider:
• the clinical question;
• possible comorbidities and alterations of the cerebral structure
• the acquisition protocol and the scanner characteristics
• the physiological distribution of the tracer
• the anatomical location of the altered concentration
• the (optional) use of semiquantitative analysis
• correlation with other clinical and instrumental data
• possible causes of false negatives / positives
The examination also depends on a the image quality. While doctors should consider the
efficiency and characteristics of their own scanner, recommended minimum parameters
are: 140 kV, 60 - 100 mA, scan time > 10 s for CT; Field of View of 30 cm, 256 × 256
(pixel 1-2 mm) matrix for PET; reconstruction algorithm: iterative methods (OSEM or
similar) with a Gaussian filter FWHM 1-2 mm; resolution recovery protocols should be
used when available. If the patient is not collaborative, it is suggested that the acquisition
be performed in “list-mode”, with a-posteriori reconstruction and with appropriate time-
frames selection.
3.3.1 Visual assessment
The maximum uptake of radiotracer at the encephalic district occurs within a few minutes
after injection, followed by rapid clearance in the following 30 minutes.
Healthy control subjects show relatively low levels of accumulation in the cortical and
cerebellar gray matter (with significant contrast between the white and the gray sub-
stance). Regional analyses show slightly higher levels of accumulation in the caudate, in
the putamen and in the hippocampus.
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Figure 3.2: Transaxial sections of amyloid PET scans showing WM/GM contrast for
a “textbook” negative (left) and a positive case (right). Arrows mark some of the most
usual areas to look for contrast loss. Color scale is inverse (dark/light colors = high/low
uptake)
The typical negative tests present high uptake only in correspondence of the white matter,
and maintain white / gray contrast in the whole brain. The typical positive test exhibit
two or more areas (lobes or significant portion of them) of reduced contrast between the
uptake of the white matter and that of cortical gray matter. The typical reference region
for contrast comparison is the cerebellum. In this site the contrast between white and
gray matter is generally maintained even in patients with AD diagnosis.
The assessment of the contrast must be carried out on all lobes (temporal, occipital,
frontal and parietal). An examination is declared as positive when at least two lobes
show significant contrast reduction.
The cerebellum generally maintains the same contrast between WM and GM, both in
patients with low and with high Aβ (Nelissen et al., 2009). For this reason, the contrast
measured in the cerebellum is usually kept as a reference.
An appropriate gray/color scale and intensity reference should be used in order to fa-
cilitate the constrast assessment. Manufacturers recommend either color or gray palette
depending on the tracer (for instance, for Flutemetamol it is recommended to set the
scale intensity at 80− 90% in the pons region).
Negative scans show relatively low levels of tracer accumulation located in the cortical
and cerebellar gray matter, with a significant contrast between the high-intensity uptake
of the WM and the low uptake of the GM. So the typical negative test shows high uptake
only at WM, where the tracer binding is non-specific. In contrast, the typical positive test
shows two or more areas of reduced contrast between the uptake in WM in the cortical
GM (figure 3.2). Thus, a key feature to distinguish Aβ positive from negative scans is the
loss of contrast gray / white matter, with the uptake of the tracer extending to the edge
of the cerebral cortex. The gaps between the two hemispheres can no longer be defined.
The scan is evaluated as positive in the presence of at least two lobes in which there is an
evident loss of contrast between WM and GM (Eli Lilly Inc., 2012; GEhealthcare, 2012).
The contrast assessment must be performed in all the lobes (temporal, occipital, frontal
and parietal) starting from the cerebellum, to get a clear picture of the base contrast in
the reference region.
There are numerous elements to be checked in the visual evaluation of amyloid PET
images, in addition to the contrast between the WM and GM signals.
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Figure 3.3: Real example of a positive (top) and negative (bottom) case. Contrast is
less pronounced than the “textbook” example. Orthogonal planes examination show the
precuneus (purple), fronto-orbital (azure) and occipital (green) regions.
In principle each tracer has its own positivity criteria, although most of them overlap
and, in general, the outcome of the examination does not depend on the specific choice
of the criteria. Particular attention should be paid to the analysis of regions known to
be typical sites of accumulation in AD: fronto-orbital, precuneus and cingulate posterior,
lateral temporal, parietal and caudate nuclei. It is appropriate that these areas be carefully
examined on the three orthogonal planes.
3.3.2 Limitations
A confounding factor to be taken into account is the presence of atrophy, where the uptake
is affected by PVE (Schmidt et al., 2015). The evaluation of scans with significant global
or local atrophy is difficult and cannot in general be supported by the amyloid PET alone.
For this reason it is recommended to have an recent MRI scan to complement the reading
with morphological information.
Another difficulty is due to the peculiar anatomy of some patients, often due to excessive
ventricles dilatation or due to traumas, vascular complications or past neurosurgery, which
make the association of the signal to the various brain structures particularly complicated.
Other difficulties may arise from noisy images, artifacts or inappropriate reconstruction
(blurring) (Schmidt et al., 2015). Suboptimal acquisitions should always be avoided as
they can compromise the examination in all but the most trivial cases.
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An additional variable to consider in the visual evaluation is the different presentation of
the available tracers: in facts, tracers behave slightly different from each other, especially
with respect to the non specific uptake in the WM and the clearance in both GM and
WM (Schmidt et al., 2015). Because of these differences, clinicians are recommended to
attend specific courses on each of the tracers they intend to use.
Visual evaluation is a fast and widely applicable procedure and most scans are easily
evaluated and categorized into negative / positive after a proper visual assessment. Still,
there is a fraction of cases (10 − 20%, but it can be as high as 30% depending on the
inclusion criteria) where this qualitative approach is not trivial.
3.4 Relationship with liquor-based amyloidosis mark-
ers
Two Aβ measure modalities have been established: cerebro-spinal fluid (CSF) Aβ42
dosage and amyloid PET. Both highly correlate with brain biopsy findings, and this
has led to consider both amyloid PET and liquor biomarkers as pathophysiological or
diagnostic markers of disease.
A potential advantage of amyloid PET over CSF Aβ42 as an early diagnostic marker is
the relative non-invasivity of the procedure and the possibility to detect regional Aβ depo-
sitions that might occur before the global neocortical signal becomes pathologic. On the
other hand, CSF analysis has the advantages that it may easily incorporate assessments
such as tau (a measure of neuronal degeneration (Blennow et al., 2010)) and hyperphos-
phorylated tau (p-tau; a potential marker of tau pathology (Buerger et al., 2006)).
There is a significant agreement between amyloid PET and β-amyloid liquor measure-
ments, and the liquor biomarkers show a diagnostic accuracy similar to that of amyloid
PET in the diagnosis of AD (Fagan et al., 2006). However, the liquor values of Aβ42 and
the results of amyloid PET show a nonlinear association.
Several studies have examined the link between amyloid PET and CSF Aβ42 (see for
instance Fagan et al. (2006); Grimmer et al. (2009); Palmqvist et al. (2015)). For instance,
while mean CSF Aβ42 is decreased in AD, this decrease may reflect plaques acting as an
Aβ42 “sink”, hindering transport of soluble Aβ42 between brain and CSF.
In terms of discrimination potential for MCI due to AD, the diagnostic accuracy of CSF
and PET biomarkers is similar, although CSF markers show an earlier response (Palmqvist
et al., 2016). The most frequent cases of mismatch are those in which amyloid PET is
negative, compared to pathological values of Aβ42 in the liquor. This effect underlines
the greater precocity of CSF positivization - which captures all the aspects of amyloid
mis-metabolism - with respect to amyloid PET, which instead shows the cerebral deposits
of amyloid when they already are in the fibrillar phase.
These results therefore suggest that the two biomarkers measure different aspects of the
amyloid pathology. In a longitudinal perspective, the liquor Aβ42 and the amyloid PET
show different trajectories along the course of the disease, where the amyloid liquor reaches
the plateau early, while the signal of the amyloid PET continues to increase dynamically
even in the later stages of disease (Palmqvist et al., 2016; Mattsson et al., 2014).
This is of great importance in a clinical setting, because the Aβ42 is a more sensitive
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marker in the earliest stages of the disease, while amyloid PET becomes a more sensitive
marker with the progression of the disease, even in the asymptomatic or paucisymptomatic
phase. Accordingly, the Aβ42 is closely linked to the status of ApoE 4 carrier, whereas
amyloid PET is more related to t-tau and p-tau in the liquor.
The Aβ42 /40 ratio is a more accurate measure of amyloidosis than just Aβ42 since it
reduces the variability due to the overall production and elimination of amyloid, thus
significantly reducing the “false positives” and “false negatives” obtained by measuring
only the Aβ42 . This is confirmed by consistent evidence showing a greater concordance
between the Aβ42 /40 liquor ratio and the amyloid PET compared to the Aβ42 alone. It
is obvious, however, that the outcome of these correlations strictly depends on the system
used to quantify both the amyloid of the liquor and the cerebral amyloidosis seen on PET.
In a routine clinical setting, and in the context of early diagnosis of AD, it may be
important to answer the question: which biomarker is better / which marker should be
performed first. Liquor analysis has the advantage of including both amyloidosis and
neurodegeneration parameters, it requires less complex and less expensive tools than
amyloid PET, but it requires a relatively invasive procedure such as rachicentesis.
Amyloid PET is less invasive and appears to have greater reliability in longitudinal eval-
uations and among different centers. To date, the main criterion of choice is the effective
availability of a reference center with the required expertise and that regularly uses one
of these markers.
Whatever the relationship between cerebral amyloidosis measured with CSF and PET
(linear or nonlinear), it is evident that both modalities are expected to provide markedly
altered results in already symptomatic patients (with MCI or mild dementia), if the
pathology in question is AD.
Chapter 4
Quantification and
semi-quantification
Figure 4.1: Qualitative representation of the
tracer activity as function of time in three
compartments or binding states: bound (the
state of interest, specific binding), the plasma
concentration (used in the Arterial Input
Function) and the free (or non specific) state.
PET quantification basically consists in
applying an appropriate mathematical
model to the collected data, in order to
extract numerical estimates of the pa-
rameters linked to the physiological pro-
cesses. This approach brings great advan-
tages compared to the qualitative evalua-
tion, as it allows to estimate the quantity
of ligand bound in a specific state and its
spatial distribution. At any given time af-
ter the tracer injection, the tracer can be
detected in several different bound states,
whose proportions are a function of the ra-
diopharmaceutical kinetics and of the bio-
chemistry involved in the transport. So the
typical intensity collected by PET is a mix
of overlapping signals, of which only one is
of interest. To isolate the desired signal component – in our case the one given by the
concentration of the tracer bound to the aggregates of Aβ – it is necessary to use a math-
ematical model that links the tracer dynamics to the intensity shown in the PET image.
In the kinetic model, each of these layers is known as a compartment (figure 4.1).
The gold standard for the quantification is the complete kinetic model with arterial blood
sample: the scan must be acquired as a continuous series of snapshots with short temporal
intervals, starting from the injection and until the concentrations reaches an equilibrium
(dynamic scanning). This protocol allows to measure the time-activity curve, that is the
trend of the radioactivity signal in every point (Schmidt et al., 2015).
The quantification (or absolute quantification) then represents the ideal method for the
in vivo measurement of the specific binding of a PET tracer to the molecular target to be
studied (Ichise et al., 2001). It is based on the identification of the compartment model
that best describes the states of the radiotracer, from the blood compartment (site of
administration) to the molecular target of interest at the cerebral level.
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In general, an absolute quantitative model allows to measure not only a simple uptake or
concentration but a series of parameters that correlate with the density of the receptors
and their affinity (Binding Potential) without the influence of the variations of regional
cerebral blood flow (rCBF) or other factors that can modify the retention and brain
wash-out.
Dynamic scanning must include the few minutes that occur after the injection, during
which the signal is dominated by the tracer flow from the plasma to the tissues, and it
is highly correlated with the brain’s regional blood flow (Gjedde et al., 2013). Then the
intensity undergoes a non-equilibrium situation, during which the specific tracer binding
approaches a plateau, followed by a period of relative equilibrium. The time required
to achieve equilibrium depends on many factors, such as the type of tracer, the regional
blood flow and the local amyloid load (Nelissen et al., 2009; Wong et al., 2010; Price
et al., 2005). By knowing the concentration of the tracer in the plasma and its temporal
trend it is possible to solve the system of differential equations which characterizes the
flow among the compartments.
In order to reduce the invasiveness due to the arterial blood sampling, simplified models
have been developed. These models exploit the intensity ratio between target regions and
a reference one, which should exhibit negligible specific uptake. Moreover, an approach
of this type allows the development of automated methods for analysis and allows the
comparison between data collected in different centers.
4.1 Compartmental models
Figure 4.2: Example of 1-compartmental
(a) and 2-compartmental models (b). Each
compartment is characterized by the tracer
concentration C in its free (F), non-specific
(NS) and specific (S) binding state.
Compartmental approaches are mathemat-
ical models used for the description and
quantification of the uptake and the clear-
ance of tracers in tissues (Innis et al., 2007;
Gunn et al., 2001; Watabe et al., 2006).
These models are used to describe systems
that vary over time, but not in space, so
that it is assumed that there are no concen-
tration gradients within the sampled vol-
ume. In addition, the concentration of the
tracer in the blood stream is treated as a
input to the system, instead of being rep-
resented by a compartment. The tracer in
the blood flux has a distinct time-activity
curve, called arterial input function (AIF).
Its typical representation is shown in figure
4.1.
Under these hypotheses, the typical com-
partmental model takes into consideration three states: a free compartment, in which the
tracer has passed the blood-brain barrier, but is not yet bound; the bound compartment,
in which the tracer is specifically linked to the amyloid aggregates; a compartment in
which the tracer is bound, but not to the amyloid (a-specific bound state) (Morris et al.
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(2004), see figure 4.2).
Each compartment is characterized by the concentration of the tracer as a function of
time. These concentrations are connected to each other by a group of ordinary differential
equations, which express the balance between the tracer mass entering and leaving each
compartment. By solving these equations it is possible to determine the quantities of
interest.
Tracer molecules are free to move among different compartments with rates determined
by a number of constants k, describing the fraction of molecules traveling from one com-
partment to another per unit of time. The temporal trajectory Ci(t) of the tracer con-
centrations C in the compartments i is the variable to be solved. More sophisticated
models include three compartments, with the separate determination of the specific and
non-specific binding. This latter model needs 6 rate constants.
Radioactive decay is generally neglected and tracer concentration at any given time is
determined by the exchange rates with the adjacent compartments.
The critical data in compartmental models is the accurate knowledge if the AIF. This
information can be acquired as:
• Arterial blood sampling: 20 to 30 samples of arterial blood are taken from the
patient, initially at short time intervals, and then at a lower rate. The samples
radioactivity is measured by an ad-hoc γ detector (Matsubara et al., 2016). This
method is rather invasive and entails a lengthy procedure, two issues that typically
discourage the arterial sampling in the clinical routine. Another limitation is the
fact that the concentration of the radiopharmaceutical is not guaranteed to be the
same both in the blood collection site (typically a peripheral artery) and in the
measurement site (in our case, the brain); in addition there can also be a time-delay
between the peripheral measure and the real AIF (Contractor et al., 2012).
• Normative data: in practice, and when the injection protocol is well known and
enforced, patients sharing common characteristics (age, weight, sex, ...) exhibit
similar AIF. The real curve therefore can be estimated from a normative dataset.
The patient needs only to undergo a few blood samples, which are used to calibrate
the normative population AIF. The main limitations of this technique consists in
neglecting the individual characteristics. In addition, the position and height of the
AIF peak may differ between this method and the previous one (Contractor et al.,
2012).
• Image-based methods: if the heart or a major artery (such as the aorta) is in the
FOV, the AIF can be derived from a region of interest (ROI) of the image (Ikoma
et al., 2008). This method is non-invasive and easy to implement; unfortunately, due
to the reduced size of the ROI from which the AIF is derived, it is essential to address
the problem of the PVE. In addition, AIFs computed on images reconstructed with
iterative methods (such as OSEM) could be plagued with systematic deviations
(Heurling et al., 2015).
AIF is considered to be the same for all the analyzed volume (in our case for the whole
brain), so that the same AIF is used fit the model on all ROIs.
For each compartment, the net flow is expressed as a rate equation in units of concentra-
tion per unit of time (dC/dt). The kinetic parameter K1 makes an exception, which has
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the unit of ml g−1 min−1; it indicates the rate of tracer exchange between the arterial
plasma and the unbound compartment of the tissues. In the simple 1-compartment model
K1 enters as
dC
F+NS+S
dt
= K1Ca − k2CF+NS+S (4.1)
The tracer concentration in the arterial blood Ca is known and given (the AIF). Solving:
Cpet = CF+NS+S = K1Ca ⊗ ek2 t
where ⊗ is the temporal convolution (Gunn et al., 2001).
In a 2-compartment model – where one compartment represents the free and non-specific
concentration, while the other represents the specific-binding concentration – the rate
equations are:
d
dt
C
F+NS
= K1Ca − (k2 + k3)CF+NS + k4CS
d
dt
C
S
= k3CF+NS − k4CS
The signal coming from the two compartments cannot be separated in the PET scan
(Gunn et al., 2001; Watabe et al., 2006) so that Cpet is the sum of the concentrations:
Cpet = CF+NS + CS =
K1
α1 − α2
[
(α1 − k3 − k4)e−α1 t − (α2 − k3 − k4)e−α2 t
]⊗ Ca (4.2)
and the α coefficients are:
α1,2 =
1
2
(
k2 + k3 + k4 ±
√
(k2 + k3 + k4)2 − 2k2 k4
)
The calculation of the kinetic parameters can be directly addressed by solving the convolu-
tion integral with iterative algorithms (Marquardt, 1963), although there exist simplified
techniques that reduce the computational cost, see for instance (Patlak et al., 1983; Logan
et al., 1990a). These latter approaches attempt to transform a non-linear problem into a
linear one, simplifying the regression procedure.
Other approaches do away with the AIF. The trick is to find a reference region for which
the specific binding is small enough to be negligible; calculating the time activity curve
(TAC) of this region from the image and comparing it to the TAC of relevant ROIs, it
is possible to deduce the ratios between the parameters of the kinetic model (simplified
reference tissue model, SRTM). The advantage of methods based on the reference region
is to be able to avoid blood sampling and analysis of metabolites, thus avoiding all errors
related to these procedures.
Typically the target region is represented by a two-compartment model, while the refer-
ence region is a single-compartment model (i.e. the amount of specific binding is con-
sidered to be negligible). The AIF in equation 4.2 is then replaced with the activity
calculated in the reference tissue, directly obtaining the kinetic parameters (Ikoma et al.,
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2008; Lammertsma et al., 1996).
Although these techniques show different advantages compared to those using AIF –
especially in terms of invasiveness – it is necessary to use them with caution due to the
assumptions implied in their methodology. For example, the existence of a specific binding
of the tracer in the reference region causes an underestimation of the specific binding in
the target region.
4.2 Quantification drawbacks and amyloid-PET spe-
cific issues
The main problem in absolute quantification methods is the general invasiveness and
patient discomfort, which makes them impractical in a clinical routine. Besides the in-
vasive procedure of AIF, all quantification techniques require a longer acquisition time
(0-60/90 minutes, depending on the tracer). This increases patient discomfort and the
concrete possibility of movement artifacts. In addition, quantification models not relying
on AIF need some key assumptions to be verified, which in most cases can lead to errors
in evaluating the kinetic parameters.
Another class of problems comes from the compartmentalized model, which often involves
a simplification of the underlying physiological process. For instance, it is necessary to
exclude the metabolites from the activity count otherwise one overestimates the AIF.
Previous studies in patients with AD dementia or MCI and in control subjects suggest that
absolute modeling of amyloid-β accumulation in the brain is feasible for 11C-PIB (Price
et al., 2005; Lopresti et al., 2005), 18F- Florbetapir (Joshi et al., 2012; Becker et al., 2013b)
and 18F- Flutemetamol (Nelissen et al., 2009; Heurling et al., 2015). In these studies it
is shown that a two-compartment model (free concentration (F) + non-specific (NS) and
specific binding (S)) and 4 constants (k1-k4) can fit experimental data and yield the BP
or the total distribution volume. However, the same studies have proposed simplified
methods, and they have validated them with the complete compartmental kinetic model.
Each simplification though can introduce a bias. Simplifications involve the reduction
of the acquisition time and the use of the input function obtained from PET images
(ROI localized in the internal carotid artery) instead of arterial samples. The reduction
of acquisition time seems to be more critical, while the use of simplified quantification
such as Logan’s graphical analysis (Logan et al., 1990b) and reference region (cerebellum,
SRTM), are rather robust.
A third class of problems lies in the fact that parameter estimation is influenced by
many factors related to image reconstruction (PVE for instance), acquisition methods
and rCBF. This latter is a crucial point in particular in the study of neurodegenerative
diseases because the reduction of rCBF can affect the radiotracer brain kinetics and
result in an erroneous measurement of simplified parameters, such as the Standardized
Uptake Value ratio (SUVr), as has been elegantly demonstrated for PIB in one longitudinal
study (Becker et al., 2013a). Thanks to simulation procedures, it has been demonstrated
that the reduction of SUVr observed in patients with AD during the 2-4 year follow-
up, which is difficult to explain in the absence of anti-amyloid therapy, was due to the
reduction of rCBF. The results were corroborated by the absence of reduction of the
Binding Potential (BP) obtained by the application of a complete compartmental kinetic
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model (Lammertsma, 2017).
It is clear that further studies are needed, that target absolute quantification in a large
number of patients. This is particularly true for the validation of simplified methods.
The correct use of quantification in patients assumes an ethical value particularly in view
of the upcoming anti-amyloid drugs, and in order to reduce the number of patients in
trials, reduce radiation exposure, etc.
4.3 Semi-quantification
Another possible approach for the extraction of meaningful quantities from PET scans
involves the use of the so-called semi-quantification methods (sometimes called relative-
quantification). Compared to absolute quantification, semi-quantification represent
a leaner alternative even though it is less accurate. The main advantage of semi-
quantification methods is that they do not require dynamic scans or the AIF, the
drawback is that they only provide simplified measures with higher uncertainties.
Semi-quantification methods rely on static scans, which consist of a single acquisition
(typical duration ≈ 20 minutes) that starts after a relatively long time from the injection
(depending on the tracer but with typical delays of ≥ 40 minutes). Static scans minimize
the time the patient has to stay in the scanner, reducing the complexity of acquisition
and analysis.
Most studies on the quantification of cerebral amyloid load in literature use semi-
quantitative methods; from oncology (Lucignani et al., 2004) to the quantification of the
cerebral amyloid load (Wong et al., 2010; van Berckel et al., 2013; Bourgeat et al., 2015;
Camus et al., 2012; Klunk et al., 2015; Thurfjell et al., 2014). Among semi-quantification
methods, the Standardized Uptake Value ratio (SUVr) is the most used and validated,
compared to the binary reading.
The SUV is defined as
SUV =
Cpet
A/W
(4.3)
where Cpet is the activity concentration in a ROI (measured by a calibrated PET scanner),
A is the injected dose (in MBq) and W is the subject’s weight. When computing the
SUV, one often considers either the average or the maximum activity in the ROI. The
ratio between two SUV is then simply
SUVr =
SUVtarget
SUVref
4.4 SUVr implementation
Following the visual evaluation guidelines for amyloid PET, it is clear that the uptake
ROIs should be placed in cortical regions. The reference region choice though is quite
arbitrary and there are several possible choices (Schmidt et al., 2015; Klunk et al., 2015):
the encephalic trunk (Klunk et al., 2015), the cerebellum GM (Price et al., 2005; Klunk
et al., 2015), or the entire cerebellum (both GM and WM) (Clark et al., 2011; Klunk
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Figure 4.4: Uptake regions for the computation of SUVr values superimposed on the
reference PET. The counts normalization region (not shown here) is the whole cerebellum.
et al., 2015; Mattsson et al., 2014).
Figure 4.3: Sample axial section of the seg-
mented cerebellar ROI
In this study we calculated the SUVr us-
ing the whole cerebellum as reference re-
gion (figure 4.3). The reason is that it
is less prone to segmentation errors than
the selection of the cerebellum gray mat-
ter alone or the brain stem, as reported in
some works in literature (Schmidt et al.,
2015).
We calculated the average cortico-
cerebellar SUVr on all scans, to compare
the ELBA score to this widely used semi-
quantification method. We used a data-
driven approach with the whole cerebellum
(white and gray matter) as reference and a
number of cortical ROIs as uptake regions,
as displayed in figure 4.4.
The SUVr information was used neither in
the blind nor in open validation phase.
The cortical regions were: medial frontal gyrus, lateral frontal cortex (middle frontal
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Figure 4.5: Data-driven SUVr probability map.
gyrus), lateral temporal cortex (middle temporal gyrus), lateral parietal cortex (inferior
parietal lobule), insula, caudate nucleus, and precuneus-posterior cingulate region. They
were obtained by a data-driven approach similar to the one described in (Klunk et al.,
2015).
Briefly, we took 50 negative and 50 positive subjects from the N and P set (i.e. those
subjects tagged negative and positive independently by all readers). Each image was
spatially normalized into MNI space and intensity normalized by the mean counts in
the whole cerebellum. Then a positive and negative mean image was generated. The
negative mean was subtracted from the positive one, the result was left-right symmetrized
and smoothed with a 3D-Gaussian filter (σ = 3 mm, figure 4.5). We found an optimal
threshold by maximization of the area under the ROC curve of the SUVr between the 50
positive and 50 negative scans.
4.5 SUVr: pros and cons
The SUVr normalizes the activity in a ROI (up to the single voxel) with the (average)
activity in a reference region (reference ROI). The reference ROI is usually chosen among
those regions for which there is minimal specific binding of the tracer. The approach used
in the SUVr is a simplified version of the SRTM and it in general good agreement with it
(Villemagne et al., 2011; Wong et al., 2010).
In amyloid PET, SUVr results were in good agreement with histopathological measures of
the density of neuritic plaques (Clark et al., 2012; Thurfjell et al., 2014; Clark et al., 2011).
In addition, by making an accurate choice of the cut-off – for example by maximizing the
accuracy of the classification with the SUVr compared to that made by visual evaluation
– binary classification based on SUVr was comparable with that obtained by CSF analysis
(Mattsson et al., 2014). Finally, the thresholded SUVr evaluation proved to be comparable
to the visual assessment (Thurfjell et al., 2014).
That said, there are some significant drawbacks in the SUVr method, the most prominent
one is that SUVr values are quite variable. The heterogeneity of SUVr values (and the
related cut-off) is due to many factors, such as the tracer used, the image acquisition
parameters and the analysis methods. All can have a significant impact on the actual
calculated values.
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The selection of the reference region, for instance, is very delicate, both because of the
anatomical choice and because of its segmentation, which can be responsible for significant
uncertainty in the counts.
The different tracers are also markedly different with respect to specific and non-specific
uptake and clearance. The SUVR values calculated from acquisitions obtained with the
different tracers are therefore not compatible (Landau et al., 2014; Klunk et al., 2015).
Obviously, also cut-off values are influenced by the tracer, even when using the same
uptake and reference ROIs. The unfortunate result is that direct comparison among
SUVr computed on scans acquired with different tracers is not possible.
SUVr values are also sensitive to the PVE: this effect tends to increase the activity in
the GM with the non-specific high uptake of adjacent WM, thus causing loss of contrast
between the two. Consequently, this effect leads to overestimation of SUVr values, es-
pecially in those subjects with low amyloid load and significant atrophy (Schmidt et al.,
2015).
Another important parameter to consider in the SUVr measurement is the acquisition
timing, that is the choice of the time interval in which to perform the PET scan. Signal
acquisition should be performed when the balance between the uptake and the clearance
of the tracer in the tissues has been reached. The achievement of this balance depends
on the tracer, but it typically occurs after about 40 minutes from the injection of the
radiopharmaceutical (Wong et al., 2010), therefore it is suggested to perform a static
acquisition of 20 minutes after the achievement of the equilibrium (van Berckel et al.,
2013; Klunk et al., 2015). In practice though, the real steady-state occurs at far longer
times and it is not truly reached at the typical acquisition starting times. For instance, it
is known that a delayed measurements results in a SUVr overestimation (Nelissen et al.,
2009; van Berckel et al., 2013). When protocols are not precisely followed the variation
in SUVr values can be significant. This is particularly important in multicentric studies,
where each center might not follow some agreed guidelines on protocols for internal or
practical reasons.
In addition, the use of SUVr in longitudinal studies has proved to be impaired by the
multiple factors that can undermine this measure (Schmidt et al., 2015; van Berckel
et al., 2013). In these studies, where the typical protocol involves a follow-up at 1–3
years, changes in amyloid load are expected to be small. Measures however, indicate that
the variability of the signal in the reference region and the variability in regional blood
flow can cause considerable uncertainty in SUVr values, resulting in a significant percent of
subjects exhibiting a decrease in amyloid load (in absence of any treatment) (van Berckel
et al., 2013). Indeed, the uptake and clearance of the tracer are related to the blood
flow; this depends not only on the type of tissue and on inter-individual physiological
differences, but also from advanced neurodegeneration (Zhang et al., 2014). Therefore
some authors even suggest that longitudinal analysis with SUVr is not recommended
(Villemagne et al., 2013).
As last remark, SUVr definition and implementation require accurate image registration
and segmentation of the cortical and reference ROIs. In general the ROI placement can be
a non trivial task due to the possible template choice, the image quality and reconstruction
paramenters, and the transformation used to implement the registration. Even though
some of these issues can be relatively compensated, analyses are prone to errors due to
the PVE when using pre-defined ROIs, particularly on the small cortical regions.
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Some studies improved on this issue by complementing the analysis with the subject MRI
(T1-weighted, volumetric and isotropic scan) (Bourgeat et al., 2015). This multi-modal
approach leads to good results at the expense of complexity and the availability of a
volumetric MRI. At the far end of multi-modal studies we should mention the PET-MRI
semiquantitative method implemented by (Cecchin et al., 2017). In this case, the SUVr
values are corrected not only by atrophy (with the direct co-acquisition of a 3T-MRI) but
also for the rCFB, thanks to the dynamic PET acquisition.
4.5.1 More on ROIs
Figure 4.6: AUC for SUVr discrimination
versus total ROI volume (mm3) and regis-
tration technique (affine, black; non-linear,
gray)
The selection of uptake ROIs even in ab-
sence of the subject’s MRI is, in prac-
tice, less dramatic than this section leads
to believe. When image registration to a
template is sufficiently accurate, we can
show that there is actually a rather broad
range of selections, all providing compara-
ble SUVr results. This is not to say that
the actual SUVr values are comparable, as
they indeed depend on the ROIs. Rather,
it means that the discrimination ability –
say – with respect to the visual assessment
is maintained.
In this work I performed a ROC analy-
sis study on SUVr discrimination ability
by varying the image registration technique
and the size of the cortical ROIs. The “gold
standard” in this case was the visual eval-
uation (negative/positive) on 100 subjects
(50 negative and 50 positive). The size of
all the ROIs were adjusted by decreasing
the threshold on the probability map (fig-
ure 4.5).
It turns out that whole-brain SUVr is quite accommodating in terms of ROI size and it
gives consistent results over a very wide range of ROI total volumes (the x-axis in figure
4.6 is logaritmic). We also see that non-linear transformation (i.e. of the scan onto the
PET template) gives significantly and consistently higher performances. This was actually
to be expected as the non-linear spatial registration allows a more accurate placement of
the anatomical districts onto the MNI space, from where we derive the SUVr ROIS.
4.6 Image analysis
Semi-quantitative analysis of amyloid PET images are prone to be implemented with au-
tomatic algorithms. Since the analysis generally consists in the evaluation of the intensity
in specific anatomical regions, all images need to undergo some processing steps to make
them comparable to each other (spatial and intensity normalization); without these steps
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Figure 4.7: Sagittal, coronal and axial section of the MNI ICBM 152 template (MRI)
the signal would be dominated by noise due to different orientations, morphology and
other physiological differences, and acquisition protocols. So all analysis presented in this
work involve some preprocessing steps, in order to make the images comparable.
The first step is a quality control; reliable measure require good quality images, with
reasonable count rates, positioning in the field of view (FOV) and optimized reconstruction
algorithms. The quality control is – at present – a human-driven task. It was necessary
to exclude extremely noisy images or images that showed important artifacts from the
analysis.
The second step is the spatial normalization onto a normative space, to ensure the align-
ment of all brain structures and for all the subjects. Spatial normalization is the most
important step to reduce the inter-individual variance. This is typically implemented
with image registration techniques and the use of a reference template, mapped onto the
normative space. The normative space used in this work is the Montreal Neurological
Institute (MNI) reference.
After spatial normalization, an optional intensity one can be applied. This can improve
certain processing steps by improving general conformity in the intensity of the analyzed
group.
Finally, there are many choices for the extraction of relevant information. A very common
strategy is to use ROIs, but in this work we shall see that other options are possible.
Statistical and geometric tools can also be applied in order to reduce inter-individual
variability or improve cohort-wise uniformity. These details will be given when appropriate
in the following chapters.
In general, all scans in this work underwent the spatial and intensity normalization. I
tried to use the bare minimum of more sophisticated pre-processing techniques with the
intent to increase usability and understanding.
4.6.1 PET dataset and subject selection
Analyses in this work were performed using three dataset: the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI 1); a selection of patients from the AVID-18 clinical trial,
1Alzheimer’s Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and
DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the Na-
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courtesy of Fondazione Poliambulanza Istituto Ospedaliero Brescia, Italy; and a multi-
centric pilot study of 147 subjects from 4 centers.
ADNI dataset
I downloaded 18F-Florbetapir scans of 244 subjects from the the ADNI archive in the
most fully processed format (series description in LONI Advanced Search: AV45 Coreg,
AVG, Std Img. and Vox Siz, Uniform Resolution, subjects identification in table 4.4).
Subjects were selected to have at least two scans (at baseline and after an approximately
2 years of follow-up), and 16 subjects came with three scans for a total of ni = 504 PET
images (i.e. 228 subject with two scans and 16 subjects with 3 scans). The ensemble
properties of these images are shown in table 4.1.
Subjects clinical evaluation was taken to be the closest diagnosis to the baseline PET
scan date. Cohorts were grouped by the ADNI core clinical criteria ((Aisen et al., 2010))
as: normal subjects (NS, N=70), early mild cognitively impaired (EMCI, N=86), mild
cognitively impaired (MCI, N=26), late mild cognitively impaired (LMCI, N=51) and
Alzheimer’s diseases (AD, N=11).
FP dataset
This dataset consists of 40 subjects acquired during the AVID-18 clinical trial at one
centre (Fondazione Poliambulanza Istituto Ospedaliero Brescia, Italy, FPA-BS) with 18F-
Florbetapir tracer and the following acquisition parameters: injected dose = 370 MBq,
acquisition time = 10 min (50 min. after the injection), image reconstruction on a 256×256
matrix with 4 iterations, 21 subset, gaussian filter with FWHM = 2 mm.
These scans were assessed to be a mix of negative and positive scans (14 and 26 respec-
tively), and the evaluation was visually confirmed by one of the expert readers (UG).
Multicentric pilot dataset (MPD)
A set of 147 subjects from a naturalistic population (age 54-87) were acquired in four
clinical centers with 18F-florbetapir PET, producing two scans per subject: an early
(0-5 min) and a late scan (50-70 min). The participating institutions were: Nuclear
Medicine Unit, Department of Health Sciences (DISSAL), University and IRCCS AOU
tional Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through
generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery
Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.;
Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd
and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer
Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Devel-
opment LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.;NeuroRx Research;
Neurotrack Technologies;Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier;
Takeda Pharmaceutical Company; and Transition Therapeutics.TheCanadianInstitutes of Health Re-
search is providing funds to support ADNI clinical sites in Canada.Private sector contributions are facil-
itated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization
is the Northern California Institute for Research and Education, and the study is coordinated by the
Alzheimer’s Disease Cooperative Study at the University of California, SanDiego. ADNI data are dis-
seminated by the Laboratory for Neuro Imaging at the University of Southern California.
38 Chapter 4. Quantification and semi-quantification
Table 4.1: Subjects and scanner ensemble statistics
Maker Model N. of scans N. of subj M/F Age
SIEMENS 1093 16 8 3/5 77.3 (8.0)
SIEMENS 1094 34 21 6/15 70.4 (6.7)
Siemens/CTI ACCEL 12 6 5/1 72.3 (7.7)
GEMS Advance 16 8 3/5 73.9 (4.3)
Philips Medical Systems Allegro Body(C) 4 4 3/1 74.0 (7.3)
SIEMENS Biograph20 mCT 1 1 1/0 72.0 (0.0)
SIEMENS Biograph64 5 5 2/3 73.5 (7.4)
GE MEDICAL SYSTEMS Discovery 600 4 2 1/1 71.5 (11.2)
GE MEDICAL SYSTEMS Discovery 710 2 2 0/2 68.2 (1.3)
GE MEDICAL SYSTEMS Discovery LS 19 11 7/4 71.2 (7.2)
GE MEDICAL SYSTEMS Discovery RX 8 4 2/2 71.5 (4.2)
GE MEDICAL SYSTEMS Discovery ST 32 23 14/9 75.1 (6.6)
GE MEDICAL SYSTEMS Discovery STE 74 43 31/12 72.6 (7.3)
Philips Medical Systems GEMINI TF Big Bore 6 5 4/1 75.2 (6.6)
Philips Medical Systems GEMINI TF TOF 16 25 12 5/7 71.5 (6.8)
Philips Medical Systems GEMINI TF TOF 64 14 9 5/4 72.7 (13.6)
Philips Medical Systems Guardian Body(C) 10 5 3/2 75.6 (5.1)
Siemens/CTI HR+ 103 54 26/28 72.9 (7.7)
Siemens ECAT HRRT 59 26 14/12 73.5 (8.6)
Philips Ingenuity TF PET/CT 3 3 2/1 70.6 (18.1)
CPS LSO PET/CT HI-REZ 45 24 11/13 70.2 (7.6)
Philips Medical Systems NULL 2 1 0/1 70.7 (0.0)
SIEMENS SOMATOM Definition AS mCT 10 10 5/5 75.1 (7.3)
- - 504 244† 128/116 72.6 (7.6)
†The number of subjects in the total is the number of unique subject identifiers. This
is not the sum of the respective column because 38 subjects were scanned on a different
system at baseline and follow-up.
Center # subjects
Gender Age Visual assessment
M / F [95% CI] Neg / Pos
FPA-BS 55 24 / 31 71 [69 72] 29 / 26
HUG-GE 44 20 / 24 72 [69 74] 27 / 17
FSM-PV 19 9 / 10 76 [73 79] 7 / 12
HSM-GE 29 15 / 14 75 [72 78] 10 / 19
Table 4.2: Multicentric Pilot Dataset demographics.
S.Martino-IST, Genova, Genova, Italy (HSM-GE, 29 subjects); Department of Nuclear
Medicine, Fondazione Poliambulanza, Brescia, Italy (FPA-BS, 55 subjects); University
Hospitals and University of Geneva, Geneva, Switzerland (HUG-GE, 44 subjects) and
Nuclear Medicine Unit, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy (FSM-PV, 19
subjects). Demographics and pre-test diagnosis are provided in table 4.2 and 4.3.
Reference PET
The reference PET (RP ) is a mean image of the FP dataset (figure 4.8). These scans were
used to generate a spatial reference only and were not included in any other development
(i.e. the ELBA and TDr semi-quantification methods).
The mix of positive and negative subjects was only used to provide a balanced template,
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Figure 4.8: Sagittal, coronal and axial section of the amyloid-PET template in MNI
space.
with the aim to provide an average image, sampled from a typical population, which is
used as registration target. In this respect, the evaluation of the single reader needs not
to be confirmed, as it only serves to generate an average, smoothed reference.
Generally speaking, the registration process between same-modality images is more robust
than the cross-modality counterpart. The main benefit of a RP therefore, was to relax
the need of matching PET scans directly onto the MNI-MRI template, either directly or
having the subject’s MRI as guide.
To generate the RP , the 40 scans underwent a recursive registration process, each step
delivering a mean template. The first step consisted of an affine registration onto the
ICBM-152 MRI template using a mutual-information metric. A intermediate PET tem-
plate was generated by averaging over the registered images. The intermediate template
was used as reference for another registration batch to generate a second reference. The
subsequent steps used an affine plus a weak non-linear registration – that is a non-linear
warping using a large (12 mm) smooth operator on the deformation field (Thirion, 1998)
– to improve on the reference image generation. The iterative process ended after no more
than 5 steps, when the generated reference did not show significant changes with respect
to the previous step.
The MNI-provided lobes, ventricles and sub-cortical regions segmentations were mapped
onto the RP and visually inspected for consistency.
Center
Diagnosis Subtype
NA / MCI / Dem. NA / Dep. / SMC MCI / MCI-AD / AD FTD / VD / CBS / MSA / SNAP
FPA-BS 9 / 12 / 34 6 / 2 / 1 12 / 0 / 19 6 / 6 / 2 / 1 / 0
HUG-GE 13 / 23 / 8 13 / 0 / 0 15 / 8 / 5 2 / 0 / 0 / 0 / 1
FSM-PV 5 / 4 / 10 5 / 0 / 0 4 / 0 / 9 1 / 0 / 0 / 0 / 0
HSM-GE 9 / 6 / 14 11 / 4 / 0 6 / 3 / 11 0 / 0 / 0 / 0 / 0
Table 4.3: Legend: NA, Normal Aging; MCI, Mild Cognitive Impairment; MCI-AD,
MCI due to Alzheimer’s Disease; SMC, Subjective Memory Complaint; AD, Alzheimer’s
Disease; FDT, Frontotemporal Dementia; VD, Vascular Dementia; CBS, Cortico-basal
Syndrome; MSA, Multisystemic atrophy; SNAP, Suspected non-Alzheimers Pathology;
Dem, Dementia; Dep, Depression.
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Chapter 5
Independent methods
There is room to improve the PET image reading by relaxing some of the constraints
imposed by the SUVr approach (such as accurate image registration and the use of pre-
determined uptake and reference ROI) while providing robust ranking among subjects
and proportionality to the visual assessment. With that, I do not wish to replace or
belittle the established visual and SUVr-based semi-quantifications. Rather, the intent is
to complement those with a novel and independent approach, with the goal of providing
more robust and diversified knowledge on difficult-to-read cases.
This chapter describes two novel methods: ELBA (EvaLuation of Brain Amyloidosis)
and TDr (Time-Delayed ratio). Both were developed on images acquired with one of the
new 18F ligands (i.e. 18F-Florbetapir).
ELBA and TDr are both intended to be proxy measures of the brain amyloid load. To-
gether they can provide a ranking system to aid in the visual assessment.
5.1 ELBA: SUVr-independent evaluation of brain
amiloidosys
ELBA is designed to deliver a whole-brain amyloid-burden estimation. Comparison to
SUVr semi-quantification, clinical evaluation at follow-up visits and cerebro-spinal fluid
(CSF) analysis is provided to complement the method validation.
The ELBA method was developed on scans currently available in the ADNI database and
acquired with 18F-Florbetapir, which was chosen by ADNI to be the reference radioligand
in the evaluation of brain amyloidosis (Jagust et al., 2010). The analysis procedure is
automatic and does not need any human supervision save for an optional check after
the spatial registration process, to ensure that the processed image is consistent and
has acceptable characteristics. In this study I first introduce the processing steps to
characterize a PET scan using two features which are combined to give the ELBA score,
next I proceed with visual assessment in blind and open sessions, finally I use the consensus
visual assessment to set a cut-off value for ELBA and SUVr measures, and compare results.
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Figure 5.1: Graphical representation of the ELBA method. From iso-intensity curves to
the geometric and intensity (contrast) features. These are combined to get a single score,
which is the arc length (curvilinear abscissa) of a curve fitted on a large dataset.
5.1.1 Working principles
The intent of ELBA is to capture intensity distribution patterns rather than actual counts
in specific ROIs. Considering the brain as a whole, I observed that geometrical appear-
ances of iso-intensity surfaces are rather characteristic in typical negative and positive
subjects, the latter showing a sparser and more convoluted appearance than the former.
In addition, whole-brain intensity histograms appear to be skewed towards higher inten-
sities in positive subjects.
As qualitative interpretation, the PET signal clusters onto the gray matter patches with
significant amyloid load, often surpassing the adjacent non-specific white matter intensity.
The presence of higher intensity patches biases the counts statistics and - when a thresh-
old is applied - gives a more complex surface (with notches and several non-connected
components).
To capture and quantify these characteristics I developed two features: one that gauges
the iso-intensity surface complexity and another that assesses the histogram propensity
towards higher values. These features are global properties of the whole brain and do not
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Figure 5.2: Intensity and spatially normalized scan with automatic segmentations: the
whole brain (blue line ‘a’) and the region of interest segmentation (magenta line ‘b’)
where the cerebellum and brain stem have been removed. Coronal view (left), sagittal
view (right)
require a reference ROI. An infographic showing these steps is provided in figure 5.1.
5.1.2 ADNI image processing
Basic image processing consisting in a spatial registration to MNI coordinates is performed
to allow the segmentation of the brain from the head. This is necessary because non-
cortical regions like ventricles, cerebellum and scalp do not carry information specific
to the amyloid burden. All downloaded scans (labelled with i, i = 1..n) were spatially
registered with an affine transformation onto the RP , delivering pi MNI-aligned images
(see paragraph 4.6.1). I then segmented the cortical surfaces (ci) and ventricles regions
(vi) from each pi by means of non-linear mapping of the available pre-segmented masks
on the reference image RP : the RP was registered with a non-linear transformation onto
the target PET and the deformation field was applied to the segmented masks.
I extracted the brain ROI bi considering all brain lobes delimited by the cortical surface
ci, neglecting the cerebellum, the brain stem and the ventricles. A sample of the image
processing result is illustrated in figure 5.2. To reduce the processing errors, longitudinal
scans from the same subject were treated as a batch from the beginning (i.e. sharing
registration parameters and masks).
Images were then measured with two methods: intensity-based and geometry-based, each
delivering a characteristic feature.
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(a) (b)
Figure 5.3: Plot a: iso-intensity partition illustration on a axial projection, related to
three percentile values of the intensity counts within the brain ROI (0.25, 0.50 and 0.75;
red, yellow and blue). Plot b: characteristic curve (rv,rs) for two typical cases: a low
and a high amyloid burden scan (thick curve / dotted curve respectively). Values are
normalized to the respective brain volume and boundary. The thin line is the bisector.
5.1.3 Implementation
Geometric feature
The selected brain volume bi is partitioned into nL = 48 iso-intensity levels 0 < lj < 1,
j = 1..nL taken at equal quantile distances of the whole intensity distribution (i.e. nL
quantiles in the interval [1 − 1/nL, nL]). The number of levels is of little consequence
provided it is chosen nL & 10 to ensure adequate sampling of the distribution (I tested
the feature outcome with nL = 16, 24, 32, 48 levels). Partitions consist of sj surfaces and
Vj enveloped volumes defined as
Vj = {num. of voxels ∈ bi, voxel intensity ≥ lj}
sj =
∑
∂Vj
1
where the ∂ symbol denotes the boundary, that is sj counts the number of voxels on the
perimeter. The sj and the enveloped volumes Vj are not required to be a connected set.
Each partition is characterized by two numbers: one representing the radius rsj of an
equivalent sphere having the same surface extent as sj, and another is the radius r
v
j of
the equivalent sphere of volume Vj, that is
rsj =
( sj
4pi
) 1
2
, rvj =
(
3Vj
4pi
) 1
3
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If I plot rvj and r
s
j for all j = 1..nL on a cartesian plane I get a characteristic curve inferiorly
bounded by the bisector line rv = rs, which is the limit for all sj being actual spheres.
The characteristic curve distances itself from the bisector line the most when the sj is
rough and notched. Because of the peculiar spatial distribution of counts in the brain,
typical appearance of the characteristic curves is rather different for amyloid-positive and
negative scans (figure 5.3).
When we subtracted the trivial bisector line, typically positive scans show a higher surface-
to-volume ratio on the higher intensity levels (low rv) with respect to the lower intensity
levels (high rv), and viceversa for negative scans.
The characteristic curve is integrated without the bisector area on the lower and higher
half of its domain D (i.e. the range of rv) to deliver the geometric feature Gi:
Gi =
∫
D1
(rs(r)− r) dr∫
D2
(rs(r)− r) dr , D1 = [min(r
v), rv/2], D2 = [r
v/2,max(rv)]
Intensity feature
This feature gauges the intensity and contrast values in bi and divides them into clusters.
The chosen clustering method was kmeans (MacQueen, 1967; Seber, 1984) with two classes
(High, Low). Since kmeans uses an iterative algorithm starting form a random sample,
to ensure reproducibility we ran it for 10 repetitions, then choosing the one with minimum
within-cluster sums of point-to-centroid distances.
In each class we computed the number of elements KHigh and KLow and the class median
intensity value IHigh, ILow. Following convention, we linearly scale the intensity histogram
so that the values corresponding to the 1% and the 99% percentiles are mapped onto the
[0, 1] interval. I then defined the intensity feature Ci as
Ci = ln
(
KHigh
KLow
ILow
IHigh
)
The intensity feature modulates the relative number of elements in the classes with their
contrast. As in the geometric feature, this latter formulation is expressed as a ratio too,
so that both features are internally (intra-subject) normalized.
ELBA score
The two image features Gi and Ci were plotted on a Cartesian plane and used to fit
a quadratic polynomial. Each point can be projected onto the curve to get two new
coordinates: a curvilinear abscissa xc (arc length) and a curvilinear ordinate yc (see figure
5.4).
The ELBA score is simply xc after a linear scaling and a shift to conveniently place the
origin at the cut-off between negative and positive scans.
Up to this point the construction of the ELBA score did not require any indication on
the subject amyloid burden, nor any hint about its age or clinical status. It was merely a
way to combine information on the geometrical distribution of PET counts in the brain
and information on the contrast between the brightest and darkest intensity components.
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Figure 5.4: ELBA scatter plot (intensity feature C vs. geometric feature G). The black
line is the quadratic model. For each scan (dots) the blue part of the line represents the
curvilinear abscissa xc (arc length), and the perpendicular line is the curvilinear ordinate
yc.
Alternative implementations
There can be equivalent implementations of the ELBA score which can replace the for-
mulas in section 5.1.3. For instance, any formulation which differentiates highly notched
vs. smoother surfaces can be used in place of the geometric feature. Similarly, intensity
bias in a scan histogram can be equivalently assessed by the following ratio
Ib =
< I > −q1
q2− < I >
where < I > is the mean intensity and q1 and q2 are the 1% and the 99% intensity
percentiles.
Even the use of the curvilinear abscissa described in section 5.1.3 is not mandatory and
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Figure 5.5: ROC curves for the ELBA score, the geometric (G) and intensity (C) features
(as computed in section 5.1.3), and the geometric mean score (
√
G× C, section 5.1.3).
Positive/Negative labels used to construct the ROC curves are those given following the
open session (section 6.1.2).
an alternative score E ′ can be formulated with a simple geometric mean1 as
E ′ =
√
G · C
In addition, given the apparent high correlation between the two features G and C (figure
5.4) one might also be tempted to use one feature only rather than a combination of the
two.
As example of possible different implementations I show in figure 5.5 the performance
comparison among the ELBA score, the geometric and intensity features alone and the
alternative score E ′.
The analysis shows the equivalence of the curvilinear abscissa vs. the geometric mean
approach, whereas the single feature comparison seems to favour the intensity feature C.
For the sake of robustness, I kept both features in the ELBA score.
1The geometric mean is often used when comparing different items to find a single “figure of merit”
when each item can span different numeric ranges.
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5.2 Time-Delayed ratio
While SUVr is based on the intensity ratio and ELBA relies on the spatial distribu-
tion, I now construct a new measure called Time-Delayed ratio (TDr), which is a semi-
quantification technique based on the tracer kinetics. Minimal kinetic information is
derived by two static scans, named “early” (E) and “late” (L).
The early scan is an acquisition starting right before the injection and lasting for ≈5
minutes (0-5 min). The late scan is the standard static scan used to evaluate the amyloid
PET (i.e. 50-70 min or 90-110 min depending on the tracer).
In the first 5 minutes, the signal is dominated by the tracer in the blood flux, so that this
scan can also be taken as a proxy of the perfusion (Wong et al., 2010; Price et al., 2005;
Contractor et al., 2012). The TDr method is similar to the SUVr but it differs from it
in terms of the definition of the uptake and reference ROIs. In its simplest form, TDr is
defined as:
TDr =
< IL > |DE
< IL > |DL
(5.1)
where < IL > is the mean intensity measured on the late scan and averaged over the
domains DE and DL. The domains are a collection of ROIs defined on the early and late
scans as follows:
DE = v ∈ E | Iv ≥ IE0 (5.2)
DL = v ∈ L | Iv ≥ IL0 (5.3)
where v represents the voxels in the scan and Iv is the intensity in v. In words, DE
and DL are a collection of voxels whose intensities are greater than a specified value (see
figure 5.7 and 5.8). So, TDr is an intensity ratio like the SUVr but the ROIs used in the
computation are neither predefined nor data driven. They are instead tailored onto the
patient, and different from patient to patient (see for instance figure 5.6) and from scan
to scan even in the same patient (in case of a longitudinal study).
5.2.1 Working principles
TDr is inspired by the absolute quantification approach. The tracer initially flows into
the blood stream ad then slowly migrates into the tissues. From the early scan it is then
possible to select high-flux tissues (restricting the search to cortical areas). Should the
β-amyloid be present in these tissue, the tracer will bind to it and we have the advantage
of knowing that it is delivered appropriately and in relatively large quantity (high uptake).
Conversely, should the β-amyloid be absent, then the tracer is most likely to be washed
out as the tissue is well perfused (good clearance).
The numerator in equation 5.1 then describes the intensity we get in the late scan averaged
on the voxels with high blood flux defined in the early scan (eq. 5.2). Clearly, a high
value of < IL > |DE corresponds to a high uptake and vice-versa.
Now, as the absolute value of this intensity can vary among subjects for a variety of
reasons (injected activity, blood flow, physiological characteristics, etc.), this intensity
must be normalized. The denominator in equation 5.1 describes the intensity we get in
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Figure 5.7: Early scan (E) and highest flow domain (DE, red outline).
the late scan averaged on the voxels with high uptake (specific or non-specific) defined in
the same late scan (eq. 5.3). Therefore, instead of using a fixed reference tissue (like the
cerebellum), I used the highest uptake domain, otherwise known as the hot spot, which
can be located in the gray or in the adjacent white matter.
Figure 5.6: Uptake domain DE on two
different subjects (one amyloid-negative and
one amyloid-positive).
This normalization frees the TDr from the
constraints of accuracy in image registra-
tion (although we shall see that there is
still a limit there) and in the definition
of a reference tissue. Another immediate
benefit is that DE and DL are defined on
images acquired with the same scanner,
and reconstructed with the same method.
This means that the PVE – although still
present – is partially “compensated” by se-
lecting both domain in the same space. Be-
cause of this definition and the selection
of high flow regions, the measurement of
amyloid load in these areas is more accu-
rate, since the contrast between the load
and the hot spot is the highest.
The DE and DL domains are function of the patient characteristics and no reference
regions or cortical atlases are needed. Domains typically consists of several distinct ROIs,
providing both local and global information. Therefore TDr values are similar to SUVr
in that they can be combined or averaged to give regional and whole-brain information.
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Figure 5.8: Late scan (L), the highest flow domain (DE, red outline) and the highest
uptake domain (DL, cyan outline).
5.2.2 MPD image processing
TDr requires only a basic image processing, consisting in a spatial registration to MNI
coordinates. Contrary to ELBA, it needs no the segmentation of the brain from the head.
The only TDr peculiar requirement is that the early scan (E) be registered onto the late
scan (L) in the native space prior to any other spatial or intensity normalization. This is
in order to minimize spatial resampling errors (figure 5.9).
Once the E and L scans are aligned in the native space, the L scan guides the transfor-
mation to put scans into the MNI space, in the same fashion as with ELBA. Therefore
all MPD scans were spatially registered with an affine transformation onto the RP .
Here too, we segmented the cortical surfaces (ci) and ventricles regions (vi) from each pi
by means of non-linear mapping of the available pre-segmented masks on the reference
image RP . We then extracted the brain ROI bi considering all brain lobes delimited by
the cortical surface ci, neglecting the cerebellum, the brain stem and the ventricles. The
bi is the confidential volume within which the domains DE and DL are defined.
5.2.3 Implementation
TDr implementation is rather straightforward. It only needs an accurate registration
of the early scan onto the late scan, so that DE ROIs can be properly applied on the
latter. For this reason the early image must be spatially normalized; this was done by
a 6-parameter linear transformation, with the L scan as fixed image. All subsequent
transformations (i.e. onto the MNI space) are applied to both E and L images alike.
After proper image registration and once in the MNI space, we apply a loose brain masks
to cut off the scalp, brain stem, cerebellum and basal ganglia, and estimate the highest
counts (DE and DL) following equations 5.2 and 5.3 with I
E
0 = 0.85 percentile and
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Figure 5.9: Sagittal, coronal and axial section of a sample early (E) and late (L) scan,
both spatially normalized and aligned onto the MNI space
IL0 = 0.99 percentile.
These values were chosen as first working hypotheses to select the high-flow cortical regions
only (IE0 ) and the hot-spot (I
L
0 ). Future work shall investigate the effect of these two
parameters and provide optimized values based on contrast measured on a normative
population.
Chapter 6
Validation
6.1 ELBA Validation
All PET images were evaluated by five independent readers: two nuclear medicine (NM)
physicians and one neurologist who have been trained to give teaching courses to NM
physicians and read more than 200 scans with supervision (expert readers) and two mod-
erately expert readers (NM physician) who read more than 200 images under supervision.
Upon coarse data examination, the readers noticed an apparent quality difference among
scans. They agreed therefore on an operational definition of “sub-optimal image quality”
for the purpose of keeping track of quality-induced mis-readings during the validation.
Figure 6.1: Transaxial picture of a sample scan considered “sub-optimal quality” by all
readers.
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They considered a subjective evaluation of low quality reconstruction, motion artifacts or
low signal-to-noise ratio according to each own clinical experience. The aim was to tag
scans whose characteristics could interfere in (or impair) the visual assessment. I provide
an example of a low quality image which was flagged by all readers in figure 6.1.
Regardless of the their quality, all scans were processed and visually evaluated. The
quality label was used for retrospective analyses only, to keep track of possible grounds
for difficult cases.
The 504 images were divided into 488 among baseline and first follow-up scans, plus 16
second follow-up scans. For the validation purpose we used the 488 baseline and follow-up
images, while the additional 16 scans were used in section 8.2.1 only.
Baseline and follow-up scans were read as independent images, all mixed together with
random order so that evaluators were very unlikely to see the same subject twice during
the reading sessions.
6.1.1 Blind phase
Images were presented after the preprocessing steps described in section 5.1.2. The blind
evaluation was carried out by each reader without interaction, without support from any
automatic analysis software, blind to the clinical data, blind to the ELBA output and
according to each reader’s own practice and experience.
Readers were initially allowed to judge on a three classes base: negative, positive and
uncertain. Readers were asked to use negative and positive tags on images where they
were absolutely confident of the visual assessment. Scans whose evaluation implied a more
elaborated visual inspection and where the possibility of doubt existed should have been
initially tagged as uncertain. In addition, readers were also asked to add a tag on the
perceived image quality.
Besides the individual evaluations, the analysis of the blind phase delivered 4 image set:
the P set and the N set, that is scans which were consistently marked as positive and
negative by all readers; the U set, that is scans which received an uncertain comment from
at least one reader; and the C set, that contains those scans which received contrasting
judgement (positive and negative together from one or more readers).
More specifically, the U set consists of scans with at least one uncertain comment but oth-
erwise no contrasting labels, whereas the C set consists of scans which received contrasting
evaluations but which may also have had one or more uncertain comment.
6.1.2 Open phase
In this phase all scans in the U and C set were presented again. Each scan was evaluated
by all five readers in an open session, with interaction, where they were invited to reach
a consensus on either negative or positive label.
This time though the ELBA output was partially used to aid in the analysis. Readers
were not made aware of the ELBA score but the image to evaluate was shown side-by-side
with two other images, ordered on the ELBA score scale: the nearest one from the P set
and the nearest one from the N set (see figure 6.3 for an example). This visualization
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Figure 6.2: Zoom on the geometric (G) and intensity feature (C) plane around a new
scan to be evaluated (blue diamond). The scan is compared to the nearest tagged cases
taken from the N and P set only, i.e. scans with concordant independent evaluation by all
readers given in the blins session (section 6.1.1). The distance is evaluated on the ELBA
plane, where the nearest positive and negative scans are indicated by the blue line.
was meant to help in the assessment, by comparing the scan under scrutiny to the most
similar, validated assets.
The original scans (i.e. not spatially normalized) were also available for consultation.
They were used to cross-check the consensus evaluation during the open discussion.
This phase shall also be used to define the ELBA score cut-off, that is by maximizing the
accuracy on the consensus-labelled dataset.
6.1.3 Comparison with SUVr-based methods
We calculated the average cortico-cerebellar SUVr on all scans, to compare the ELBA
score to this widely used semi-quantification method. We used a data-driven approach
with the whole cerebellum (white and gray matter) as reference and a number of cortical
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Figure 6.3: A trans-axial representation of the three scans from figure 6.2 as sample of
the additional information used in the open phase session (section 6.1.2).
ROIs as uptake regions, as displayed in figure 4.4. The SUVr information was used neither
in the blind nor in open validation phase.
SUVr measures were provided by ADNI too, but only on a fraction of the baseline PET
scans (111). The ADNI-provided values are calculated according to protocols described
in (Jagust et al., 2010) and they are the average cortical-cerebellar SUVr computed with
two methods: one with the syngo PET Amyloid Plaque (sPAP) software and another
with the Avid Semi-Automated Method (AVID, (Hutton et al., 2013)). We checked that
SUVr values computed with the data-driven approach agreed with those already provided
on the subset of baseline scans using correlation and linear regression analysis.
The final SUVr cut-off was chosen to maximize accuracy using the consensus nega-
tive/positive labels after the open phase session.
6.1.4 Comparison with CSF Aβ42 quantification
CSF was acquired by lumbar puncture following procedures and criteria identified by
ADNI (analysis details and quality control procedures are available at http://adni.
loni.usc.edu/). The biomarker data set used in this study was taken from the file series
upennbiomk4.csv to upennbiomk8.csv. We considered CSF and PET data whose mea-
surements were closest in time, restricting to lumbar punctures and PET measurements
performed within 100 days of each other, which resulted in a selection of 203 subjects.
The cut-off on CSF Aβ42 values was 174 ng/L (from (Mattsson et al., 2014)), a value
Mattsson found to be optimal to maximize accuracy between stable and progressive MCI.
We compared CSF with ELBA and SUVr scores and with visual assessment. We also
evaluated the diagnostic performance for NS versus AD (57 vs. 51 subjects respectively),
where clinical assessment was taken at the latest possible follow-up visit.
6.1.5 Clinical follow-up
The latest clinical evaluation was checked and compared to the initial assessment. We
found 78 subjects who had their assessment reviewed from baseline (latest clinical data
sheet downloaded on May 10, 2016). The average time to conversion was 35 ± 10
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(a) (b)
Figure 6.4: Injected dose (a) and scan start time after the injection (b) versus ELBA
score. A linear model was used to fit the data. 95% conf. lev. on the line slope shows
that there is no significant dependence of both variables on the score.
months (mean and standard deviation). They were divided into 4 classes according to
the baseline/follow-up assessment: MCI→AD (46), MCI→NS (16), NS→MCI (10) and
NS→AD (6).
Their ELBA and SUVr scores at baseline were used to measure consistency between semi-
quantification methods and the agreement with the diagnosis at baseline and follow-up.
When present, CSF Aβ42 level was used to help discussing borderline cases and evaluate
diagnosis agreement with the biomarkers.
6.1.6 Further methodological considerations
We checked for dependency on tracer doses administered, scan start time after the in-
jection and white matter integrity as possible factors which might influence the inten-
sity mapping. Data set containing scan information were downloaded from ADNI (files
av45meta.csv, ucd adni1 wmh.csv and ucd adni2 wmh.csv, additional analysis details are
available at http://adni.loni.usc.edu/). These additional data were available for 242
scans.
All parameters were linearly regressed against the ELBA score, showing no significant
trend (95% CL on the line slope include the zero). A visual representation of this analysis
is found in figure 6.4 and 6.5.
In addition, we estimated the generalized accuracy, sensitivity and specificity of ELBA
and SUVr scores vs. the visual assessment (open phase) by means of an iterative proce-
dure. Briefly, we randomly selected 50% of the PET datasets as the training group – for
the coefficient estimation for SUVr and ELBA – and 50% of the PET datasets as the test-
ing group (for the cross-validation of the estimated coefficients). Each group contained
approximately an equal number of positive and negative scans, based on the concordant
judgement of the experts (i.e. after the open session). Cut-off values for SUVr and ELBA
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Figure 6.5: White matter (WM) hyperintensity volumes versus ELBA score and SUVr
score (both plotted as zscores). 95% conf. lev. on the line slope shows that there is no
significant dependence of the WM hyperintensity volumes on both scores.
scores were computed on the training group (maximizing accuracy) and applied to the
testing group. The procedure was iterated 500 times.
6.2 TDr Validation
A thorough validation of TDr is still missing. In particular, we have no hystopathological
study nor a direct confrontation with CSF values. This is due to the fact that TDr require
a specific acquisition protocol which, to date, is only available at few high-level research
centers. Therefore large dataset like ADNI, which embed much of the needed information,
could not be used.
The requirement of two acquisitions per subject is not incompatible with clinical practice
per se but it assumes well trained nuclear medicine physicians as well as technical support
to properly manage the scanner timing, acquisition and patient management.
The early acquisition timing is particularly delicate because it influences the choice of DE
and therefore the result of semi-quantification with the TDr method; a 10-minute delayed
early acquisition from the agreed protocol (0-5 min from the injection) may not provide
the correct information, dominated by the blood flow signal.
Thus TDr has only been partially validated, that is by comparison with visual assessment
and the two other validated semi-quantification methods: SUVr and ELBA.
We used the Multicentric Pilot Dataset (MPD, section 4.6.1), whose PET evaluation
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labels (negative / positive) and clinical data were provided independently and blind to
the quantification analysis. In addition, no consensus label was applied to the scans so
that visual assessment reflects each center’s expertise and criteria. From the point of view
of TDr though, we can consider the visual evaluation as blind (in a similar fashion as in
ELBA, section 6.1.1).
6.2.1 Comparison to SUVr and ELBA
We compared TDr with respect to the two other semi-quantification methods using Pear-
son correlation and the residual analysis. No scans were excluded and the correlation was
computed on the whole dataset (no single-center evaluation).
We also computed all the semi-quantification cut-offs on the MPD dataset, following the
criteria of maximum accuracy on the visual assessment (similarly to what was done in
ELBA on the ADNI dataset).
Chapter 7
Results
7.1 ELBA
7.1.1 Blind and open phase performance
The score distribution was grouped by visual assessment and results are displayed in figure
7.1, where we show the single reader evaluation and the combined set after the blind and
the open sessions (sections 6.1.1 and 6.1.2). An equivalent plot using the curvilinear
ordinate yc is provided in figure 7.2.
Of the 488 scans, 186 were consistently marked as positive by all readers (P set), 217
marked as negative (N set), 63 received an uncertain comment from at least one reader
(U set) and 22 received contrasting judgement (positive and negative together, C set).
The agreement among the readers after the blind session was measured by the intraclass
correlation coefficient (ICC) and was found to be ICC=0.94, (p < 10−4).
Scans labelled uncertain were rather consistent both in number – 59, 45, 49, 42 and 48 for
AC, IB, UG, SM and FN respectively – and ELBA score. Moreover all readers consistently
tagged 34 scans as uncertain. Not surprisingly, 45 out of 63 (71%) of all uncertain scans
were also flagged as “sub-optimal quality” by at least one reader.
To define the cut-off value on the score we used the open phase results. The cut-off was
chosen to maximize accuracy and the original curvilinear abscissa (xc) was scaled and
shifted to have cut-off = 0 and the mean score on the negative scans = -1 (lower x-axis in
figure 7.1). The linear scaling is not a necessary step per se, it is applied only to facilitate
the score interpretation.
The discriminating power was measured by the area under the receiver operating char-
acteristic curve (AUC), giving AUC= 1.000 for N vs. P in blind condition (i.e. on the
scans on which all readers independently concurred), and AUC= 0.997 [0.993 - 0.999] for
negative vs. positive (accuracy= 0.97) after the open phase discussion (CL=0.95 within
brackets).
We also show the distribution of the score grouped by clinical cohorts in figure 7.3; 244
subjects are plotted, grouped by their clinical classification at baseline. The values on the
y axis are the average between the baseline and the follow-up ELBA scores. To enhance
the reading, subjects in figure 7.3 are also grouped by age: for each cohort, the leftmost
and rightmost dots represent subjects of age < 70 and > 70 years respectively.
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Figure 7.1: Visual evaluation versus the ELBA score (or equivalently the curvilinear ab-
scissa) before and after the blind phase session. negative, positive and uncertain labels are
given by each reader (AC, FN, IB, SM and UP). In the blind session summary (‘Blind’),
P and N refers to scans consistently (i.e. by all readers) tagged positive and negative re-
spectively. U refers to scans which received at least one uncertain tag but no contrasting
assessment; C refers to scans which received contrasting assessment (even when together
with uncertain tags). The open session summary (‘Open’) shows the dichotomic consen-
sus. Circles are centred on the median value of the respective cohort and their areas are
proportional to the sample size. The vertical line marks the cut-off. Thick lines mark the
25% and 75% percentile, thin lines extend up to to 1.5 times the interquartile range.
7.1.2 Comparison with SUVr-based methods
Figure 7.11 and table 7.2 present semi-quantification values and binary summary sep-
arately for the different diagnosis groups, using the visual assessment after the blind
session. Figure 7.4 shows the comprehensive ELBA score vs. SUVr semi-quantification
on all scans labelled according to the visual evaluation after the open phase session, the
confusion matrix is provided in table 7.1a and 7.1b. In these figures and tables the op-
timal SUVr cut-off is 1.23 and it was computed maximizing the accuracy using the open
session results, in the same way as with the ELBA score.
The SUVr AUC= 0.978 [0.964 - 0.985] (accuracy= 0.94). The Pearson correlation between
ELBA and SUVr scores is r = 0.86 (p < 10−4).
We matched our SUVr computation on 111 baseline scans which were provided with
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Figure 7.2: Set distribution over the curvilinear ordinate yc after the blind phase session.
P and N refers to scans consistently (i.e. by all readers) tagged positive and negative
respectively. U refers to scans which received at least one uncertain tag but no contrasting
assessment; C refers to scans which received contrasting assessment (even when together
with uncertain tags). Circles are centred on the median value of the respective cohort
and their areas are proportional to the sample size. Thick lines mark the 25% and 75%
percentile, thin lines extends up to to 1.5 times the interquartile range.
independent SUVr values by ADNI (sPAP and AVID methods). Pearson correlation is:
r = 0.98 (p < 10−4) this work vs. sPAP; r = 0.99 (p < 10−4) this work vs. AVID. The
least square line y = ax+ b between our SUVr and the AVID one has a slope [CL=0.95]
a = 0.90 [0.87, 0.92] and intercept b = 0.07 [0.03, 0.10] which translates in an equivalent
optimized cut-off = 1.18 on the AVID values.
Using the cross-validation procedure to establish cut-off values and estimate the gener-
alized performance (section 6.1.6) we found that the combined accuracy, sensitivity and
specificity for ELBA are 0.96, 0.97 and 0.95 respectively. Similarly, SUVr results are:
0.95, 0.96 and 0.93. The ELBA cut-off range was found within the interval [-0.14 – 0.18]
(95% CL).
62 Chapter 7. Results
Figure 7.3: Mean (baseline and follow-up) ELBA score distribution vs. clinical cohort.
Dots (subjects) are shown with the median (red line), the 95% conf. level on the me-
dian (yellow band) and the interquartile range (azure band). In each cohort, the leftmost
[rightmost] dots represent age class < 70 [> 70] years old. NS = cognitively normal sub-
jects, EMCI/LMCI/MCI = early- / late- / mild cognitive impairment, AD = Alzheimer’s
Disease.
7.1.3 Comparison with CSF Aβ42
The scatterplot between baseline ELBA score and CSF Aβ42 concentration is provided in
figure 7.5, where the open-phase visual assessment was used to group data.
Concordance between ELBA score and Aβ42 score classification was achieved in 184 out
of 203 (90.6%) instances; in 7.5% of patients an altered Aβ42 score was found with normal
ELBA score and, on opposite, 1.5% of patients had a (slightly) increased ELBA score
with normal Aβ42 levels.
The related SUVr representation is in figure 7.6. The confusion matrix for CSF versus
visual assessment (open phase), ELBA and SUVr scores is provided in table 7.3, where
the accuracy is found to be 0.90, 0.91 and 0.89 respectively.
The number of subjects with confirmed NS and AD clinical status at follow-up and with
CSF analysis is 108. The area under the ROC curve (auc, CL=0.95) for NS (57) versus
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Figure 7.4: ELBA and SUVr scores scatter plot for all scans. ‘n’ and ‘p’ tag the consensus
evaluation after the open phase session. Dotted lines mark the cut-off values.
AD (51) is found to be auc= 0.88[0.78− 0.95] (CSF), auc= 0.96[0.90− 0.98] (ELBA) and
auc= 0.92[0.84− 0.97] (SUVr). A graphical representation is in figure 7.7.
7.1.4 Clinical follow-up
Figure 7.10a shows the scores for those subjects whose clinical evaluation changed over
time. The agreement between ELBA and SUVr dichotomized scores is 97.4%. Most
MCI→AD (89%) do fall into the SUVr positive / ELBA positive quadrant, as well as
most MCI→NS (87.5%) fall into the SUVr negative / ELBA negative quadrant.
When considering CSF Aβ42 values – which were available for 63 out of 78 converters –
the agreement with ELBA was slightly better than with SUVr (93.7% vs. 90.5%, figure
7.10b and 7.10c).
Very limited discrepancies with the clinical evaluation are apparent. For instance, there
are two subjects (1 MCI→AD and 1 NS→AD) who exhibit consistently negative mark-
ers (ELBA, SUVr and CSF) despite their final clinical assessment, another NS→AD is
borderline negative for CSF and ELBA and borderline positive for SUVr.
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Table 7.1: Confusion matrix for ELBA score / SUVr (a) and visual assessment (open
session, b)
a)
N=488
ELBA
positive negative
SUVr
positive 190 25
negative 13 260
b)
SUVr ELBA
Visual assessment
positive negative
positive positive 189 1
positive negative 7 18
negative positive 7 6
negative negative 1 259
7.2 TDr
TDr was validated on the Multicentric Pilot Dataset, which has significantly less scans
and centers than the ADNI dataset used in the ELBA validation. While this dataset has
enough subject and variety to serve as validation, we lack proper information on clinical
follow-up, CSF and other auxiliary steps like the consensus-open session. For this reason
we limit the results to a descriptive statistics.
First we show the TDr statistics per center. As seen in figure 7.8 all centers but Geneva
share compatible statistics. This discrepancy though cannot be judged at face value be-
cause it can depend on several factors such as the patient selection and – most importantly
– on the acquisition protocol.
Performancewise, TDr shows excellent results both when grouped by each center and
globally. The AUC with respect to the visual assessment is: AUC=1.00 (Brescia, Ginevra,
Pavia) and AUC=0.99 (Genova). Overall, TDr scores AUC=0.99. For comparison, the
respective SUVr and ELBA performances are summarized in table 7.4.
In terms of correlation with other semi-quantification methods, results are summarized in
figure 7.9 and table 7.4. We find that TDr significantly correlates with the two validated
methods, although it clearly relates better with ELBA, particularly when we consider the
negative and positive classes separately. The cut-offs shown in figure 7.9 are: c
SUV r
= 1.12,
c
ELBA
= 0.90, c
TDr
= 0.62.
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ELBA/SUVr Visual assess. Baseline clinical eval.
quadrant (blind) NS EMCI MCI LMCI AD Scan tot.
-/-
N 81 71 21 31 4 208
P 0 0 0 0 0 0
U 20 18 3 6 0 47
C 3 2 0 0 0 5
-/+
N 4 5 0 0 0 9
P 1 2 0 1 0 4
U 2 4 1 1 0 8
C 2 2 0 0 0 4
+/-
N 0 0 0 0 0 0
P 3 1 0 2 0 6
U 1 2 0 0 0 3
C 0 4 0 0 0 4
+/+
N 0 0 0 0 0 0
P 19 57 25 57 18 176
U 2 0 1 2 0 5
C 2 4 1 2 0 9
Scan tot. 140 172 52 102 22 488
Table 7.2: Binary semi-quantification versus visual assessment and clinical evaluation.
Classification summary of all scans using the visual assessment after the blind session
(see figure 7.11). P and N refers to scans consistently (i.e. by all readers) tagged pos-
itive and negative respectively. U refers to scans which received at least one uncer-
tain tag but no contrasting assessment; C refers to scans which received contrasting
assessment (even when together with uncertain tags). NS = cognitively normal sub-
jects, EMCI/LMCI/MCI = early- / late- / mild cognitive impairment, AD = Alzheimer’s
Disease. Values represent the number of scans in each class.
Table 7.3: Confusion matrix for CSF Aβ42 concentration versus the consensus visual
assessment (a), ELBA (b) and SUVr scores (c).
a)
N=203
Visual evaluation
negative positive
Aβ42 [ng/L]
> 174 100 3
< 174 18 82
b)
N=203
ELBA score
< 0 > 0
Aβ42 [ng/L]
> 174 100 3
< 174 16 84
c)
N=203
SUVr score
< 1.23 > 1.23
Aβ42 [ng/L]
> 174 96 7
< 174 15 85
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Figure 7.5: CSF Aβ42 level versus baseline ELBA. Markers are grouped by binarized
ELBA score being either concordant or discordant with the consensual visual evaluation
(open phase). Cut-off are marked with thin dotted lines.
Table 7.4: Performance (AUC) versus visual assessment on the Multicentric Pilot Dataset
(left). Pearson r (p-value) between methods (right).
Site TDr SUVr ELBA
Brescia 1.00 0.99 1.00
Ginevra 1.00 0.94 0.99
Pavia 1.00 0.94 0.98
Genova 0.99 0.76 0.99
Whole set 0.99 0.92 0.99
Methods Pearson r (p-value)
whole set negative positive
TDr/SUVr 0.65 (< 10−3) 0.21 (0.068) 0.09 (0.429)
TDr/ELBA 0.85 (< 10−3) 0.57 (< 10−3) 0.32 (0.006)
SUVr/ELBA 0.67 (< 10−3) 0.35 (0.002) 0.03 (0.786)
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Figure 7.6: CSF Aβ42 concentration versus baseline SUVr score. Markers are grouped
by binarized SUVr score being either concordant or discordant with the visual evaluation.
Cut-off are marked with thin dotted lines.
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Figure 7.7: ROC curves for 57 cognitively normal (NS) and 51 with Alzheimer’s disease
(AD) subjects with confirmed diagnosis at follow-up visits. 95% CL are provided on the
area under the ROC curves (auc).
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Figure 7.8: Raw TDr scores versus center in the Multicentric Pilot Dataset. Left:
TDr distribution versus center; median (red line), median CL (0.95%, red area); ± one
standard deviation (blue area); dots are the single data points. Right: TDr distribution
versus visual assessment split by center; median (red line); 25% and 75% are within the
colored boxes.
Figure 7.9: Scatter plot of all three semi-quantification methods versus the visual assess-
ment. Black horizontal and vertical lines show the cut-off.
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(a)
(b) (c)
Figure 7.10: Baseline CSF Aβ42, ELBA and SUVr scores grouped by clinical evaluation
(baseline→follow-up) for subjects whose initial assessment changed at some later visit.
Cut-off are marked with dotted lines. In plot (a) the number of subjects is 78. In plot (b)
and (c) the number of subjects is 63 out of 78, that are those for which CSF data were
available too. NS = cognitively normal subjects, MCI = mild cognitive impairment, AD
= Alzheimer’s Disease.
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(a) (b)
(c) (d)
Figure 7.11: ELBA score / SUVr values versus visual assessment after the blind session,
grouped by baseline clinical evaluation. P and N refers to scans consistently tagged
positive and negative respectively. U refers to scans which received at least one uncertain
tag but no contrasting assessment; C refers to scans which received contrasting assessment.
NS = cognitively normal subjects, EMCI/LMCI/MCI = early- / late- / mild cognitive
impairment, AD = Alzheimer’s Disease.
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Advanced topics
8.1 Parcellation
So far, we have only considered a semi-quantitative analysis performed on a macro-region
(bi) that contains all cortical areas subject to accumulation of Aβ.
Several studies (Clark et al., 2012; Nelissen et al., 2009; Thurfjell et al., 2014) have assessed
the amyloid load in specific brain regions (frontal, lateral, temporal, parietal, anterior
cingulate and precune cortex), as these regions show greater tracer retention in positive
subjects than in the normal control (Ziolko et al., 2006; Engler et al., 2006), consistently
with pathological studies of accumulation of amyloid (Braak and Braak, 1991; Thal et al.,
2002). In some cases, the analysis of specific regions can provide a more sensitive measure
than the average over the entire cerebral cortex (Rodrigue et al., 2012; Yotter et al., 2013).
For these reasons it is interesting to perform a semi-quantitative regional analysis.
From the MNI Cortical Atlas we selected the subdivision of the cortex and adjacent
tissued into 25 contralateral regions Pk, k = 1..50 (figure 8.1). The Pk were added to the
macro-region consisting of the whole brain, thus obtaining 51 indicators of the amyloid
load per scan and per method.
The integration of a predefined parcellation with the specific ROIs relevant to each semi-
quantification method is not straightforward. The proposed solution is not necessarily
the best nor the only one. This adaptation though is useful to compare several methods
Figure 8.1: Sample cross-sections of the parcellation regions Pk.
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Figure 8.2: Regional AUC versus visual assessment on the parcelled atlas.
on the same ground.
The regional analysis was carried out with some slight differences with respect to the
three methods (SUVr, ELBA and TDr) due to their peculiar approach to ROIs.
8.1.1 SUVr regionalization
The normative dataset used to compute SUVr ROIs (see paragrah 4.4) was reworked to
give a whole-image, voxel-based value that can be used to weight the uptake information
on each voxel. This whole image map expresses a value w proportional to the AUC
between negative and positive scans at the voxel level: w = 2(AUC − 0.5), see figure 4.5.
The regional SUVr value S on the region Pk is therefore
Sk =
∑
i∈Pk wiIi∑
i∈{∪kPk}wi
where i is the index of all voxels, Pk is the parcellation under consideration, {∪kPk} is
the union of all parcellation (i.e. the atlas), Ii is the normalized intensity in the voxel i
(intensity normalized to the whole cerebellum).
Obviously, SUVr values do not exhibit the same discrimination ability on all Pk. An
approximate performance indicator is shown in figure 8.2, where the AUC is color-encoded
on the parcellations.
8.1.2 ELBA regionalization
The peculiar treatment of intensity patterns in ELBA do not allow the direct parcellation.
For instance, ELBA cannot work on strict cortical Pk as it measures the intensity distri-
bution when passing between the white and the gray matter. In addition, the definition
of iso-intensity surfaces require a relatively big volume (i.e. one with a sufficient number
of voxels) so we expect that ELBA would perform poorly on small Pk.
To partially overcome these issues, each Pk undergoes a dilation with a radius of 4 mm
(Pk → Pˆk). This provides an enlargement of small parcels and ensures that the white
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Figure 8.3: Regional AUC versus visual assessment on the parcelled atlas.
Figure 8.4: Sample parcellation region Pk (orange) and its extension Pˆk (blue) superim-
posed onto a sample negative scan.
matter adjacent to the gray cortical one is included in the Pˆk. Figure 8.4 shows an example
of the enlarged parcellation Pˆk.
The drawback is that Pˆk are now overlapping among themselves. This though does not
constitutes a real problem as the regional ELBA values are loosely related with the global
one. Indeed, the sphericityG (paragrah 5.1.3, geometric feature) of an iso-intensity surface
computed – say – on two adjacent regions Pˆk ∪ Pˆh is not the sum of those computed on
the single regions. The same reasoning holds for the intensity feature I (paragrah 5.1.3,
intensity feature) Therefore, in ELBA, the regional values might be completely different
from the whole brain assessment. Figure 8.3 shows the color-encoded AUC.
8.1.3 TDr regionalization
This method is the most adaptable to parcellation. The relatively high spatial density
computed from the early scan ensures that in each region Pk there is a sufficient number
of TDr ROIs to be relevant for the analysis. The regional TDr values comes therefore
from the intersection between each Pk and the TDr ROIs from the early scan. The related
AUC plot is in figure 8.5.
We can see that regional performance is rather scattered, particularly when SUVr is
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Figure 8.5: Regional AUC versus visual assessment on the parcelled atlas.
Figure 8.6: Compared AUC on the parcelled atlas. Marker area is proportional to the
parcellation volume. The biggest marker (light blue) is the whole brain.
involved (figure 8.6).
8.2 Longitudinal studies
Amyloid load quantification is especially important in the context of longitudinal analysis.
With the foreseen availability of disease-modifying drugs that will likely induce anti-
amyloid effects, it is important to evaluate a change in amyloid load with great accuracy.
Unfortunately, current semi-quantification techniques are still rather lacking in terms of
reproducibility and test-retest error. In this chapter I will show a detailed comparison of
ELBA and SUVr in terms of measure accuracy in a longitudinal setting. TDr will also be
investigated, albeit with a different approach.
76 Chapter 8. Advanced topics
8.2.1 ADNI dataset analysis with ELBA and SUVr
We computed the annualizes score change (ASC) using follow-up scans. For the 228
subjects with a baseline and a follow-up scan we used the formula
ASC =
sf − sb
tf − tb
where f and b label the follow-up and baseline score and subject’s age. For the 16 subjects
with two follow-up we computed the least square linear regression
s+  = mt+ b
of the score s versus time t (b is the intercept and  the residuals) and the ASC is simply
ASC = m
To compare the numbers with other indexes (such as those computed with SUVr quan-
tification) we considered the normalized quantity
δ =
ASC
iqr(s)
× 100
where the interquartile range (iqr) of the score s is used as normalization factor to estimate
the relative score change over the observed population variability.
Using the 16 subjects with three scans each we attempted to estimate the analysis stability
and robustness. With the present data we could not evaluate a test/retest paradigm on the
same subject (i.e. two repeated scans with subject reposition) so we used the residuals  on
the linear regression of the score versus time as a proxy. This works under the hypothesis
that the amyloid burden piles up slowly and linearly at least within the follow-up time
(approx. 4 years) – an assumption that agrees with the accepted neuropathological models
– and assuming that the technical errors on repeated scans are independent from the
subject’s amyloid burden.
Deviation from the linear behaviour is then used as a surrogate to the test/retest error
and treated as analysis uncertainty - due to protocol, image acquisition, reconstruction
and processing - and used to estimate the error on the single examination. It can be thus
compared to literature works on the various Aβ ligands ((Joshi et al., 2012; Vandenberghe
et al., 2013; Klinger et al., 2013) and (Lopresti et al., 2005)), which show an average
test/retest relative error using the global SUVr measurement in the range 3%− 7%.
Obviously, the measured uncertainty would not be due to the feature processing only, but
also to the different acquisition conditions, scanners and reconstruction parameters. For
instance, we remark that among the 16 subjects with three scans, 11 were acquired on a
single scanner on baseline and follow-up, and 5 subjects were acquired with two different
scanners at some follow-up.
Finally, we selected a subset of subjects with either negative or borderline ELBA score
(i.e. ELBA¡0.5) which were also evaluated by CSF analysis. These subjects were divided
into three groups, of progressively lower average Aβ42 concentration (ng/L): group A,
Aβ42 > 230; group B, 174 < Aβ42 < 230; group C, Aβ42 < 174.
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Figure 8.7: Relative (δ, interquartile-range normalized) and absolute annualized score
change (ASC) for ELBA vs baseline score. A quadratic model and the CL band on the
model are superimposed. Subjects with three scans (triangles) are marked separately
from subjects with only two scans (dots).
These three groups contained an approximately equal number of subjects (52, 48 and 34
respectively) where the above-cutoff ensemble was divided into A and B to better reflect
the possible trend in longitudinal behaviour with respect to CSF outcome. An analysis
of variance was applied to check for significant differences among groups.
Results
Longitudinal analysis on the subjects with a baseline and one follow-up scans showed
rather scattered values, although a pattern could be clearly discerned. Figure 8.7 shows
the distribution of δ vs. the average ELBA score together with a 2nd-order polynomial
model, used to fit the data. The interquartile value used for normalization of the ASC is
iqr(s) = 1.89. An equivalent graph using SUVr values is reported in figure 8.8.
Subjects with two follow-up scans are also plotted on the same graph. Cohortwise, these
subjects belonged to NS (5), EMCI (2) and MCI (9). Using these latter 16 subjects we
computed the residuals  from the linear fit, to be used as proxy of the test/retest error.
The standard deviation of the residuals is approximately σ = 0.084, which amounts to
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Figure 8.8: Relative score change (δ, interquartile-range normalized) for SUVr vs baseline
score. A quadratic model and the CL band on the model are superimposed. Subjects with
three scans (triangles) are marked separately from subjects with only two scans (dots).
an estimated relative error σr = σ/iqr(s) = 4.4% (σr = 2.3% if we normalize on the
95% percentile of the score range). The equivalent SUVr values are σSUV r = 0.023 and
σr = σSUV r/iqr(SUV r) = 4.6%
We computed also the relative annualized score change δ grouped by cohorts. Reported
values (expressed in %/year) are the median and its confidence interval (at CL=95%):
δ = 4.6 [3.1, 6.1] (NS), δ = 8.1 [6.6, 9.6] (EMCI), δ = 3.4 [0.6, 6.2] (MCI), δ = 6.0 [3.9, 8.2]
(LMCI), δ = 5.6 [−0.7, 11.9] (AD). A t-test found the values to be significantly different
between EMCI and NS cohorts (p = 0.02) and between EMCI and MCI cohorts (p = 0.02).
Finally, we analized the ELBA ASC against the CSF Aβ42 concentration (figure 8.9 and
figure 8.10 for SUVr ASC) for 134 subjects with negative or borderline ELBA score (¡0.5).
The Pearson correlation between the two quantities is small but significant (r = −0.30,
p = 0.0004). The grouping by CSF intervals allows to see a trend beyond the noisy ASC
data. From the highest mean Aβ42 concentrations to the lowest, the ASC ranges from
group A = 0.07 [0.03 – 0.10] to group B = 0.14 [0.11 – 0.17], to group C = 0.20 [0.14
– 0.27] (mean and 95% CL on the mean). The analysis of variance indicates that group
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Figure 8.9: CSF Aβ42 versus ELBA annualized score change (ASC) for 134 subjects
whose baseline ELBA score was < 0.5 (i.e. negative or borderline according to ELBA).
Subjects are divided by CSF range (ng/L) into three groups: A (230 < Aβ42), B (174 <
Aβ42 < 230) and C(Aβ42 < 174). The corresponding ensemble statistics is summarized in
the boxplot, where the box length spans the 25% to the 75% ASC percentile, the white dot
and the white triangles are the mean and the 95% CL on the mean respectively. Groups
A/C, and B/C are significantly different.
A and C, as well as group B and C are significantly different (p < 10−4 and p = 0.02
respectively). The corresponding analysis on SUVr ASC gives: group A = 0.005 [-0.00 –
0.01], group B = 0.01 [0.00 – 0.02] and group C = 0.03 [0.01 – 0.04]. The between-groups
comparison is p = 0.001 (A vs. C), and p = 0.03 (B vs. C).
8.3 Test-retest: a cross-sectional approach
The trend in amyloid load that can be estimated by longitudinal analysis depends on the
test-retest error of the measure. In paragraph 8.2.1 we have seen that the ASC has a
rather large uncertainty, and that uncertainty is severely limiting the effectiveness of a
longitudinal measure and its clinical potential.
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Figure 8.10: CSF Aβ42 versus SUVr annualized score change (ASC) for 134 subjects
whose baseline score negative or borderline. Subjects are divided by CSF range (ng/L)
into three groups: A (230 < Aβ42), B (174 < Aβ42 < 230) and C(Aβ42 < 174). The
corresponding ensemble statistics is summarized in the boxplot, where the box length
spans the 25% to the 75% ASC percentile, the white dot and the white triangles are the
mean and the 95% CL on the mean respectively. Groups A/C, and B/C are significantly
different.
A way to model the actual semi-quantification measure m is to think of it as the sum of
two contributions: the ”true” amyloid load due to the physiological variability a, and the
measure error (both due to the acquisition and to the semi-quantification) δa. So we can
write
m = a+ δa
If the measure error is unbiased and with zero mean
< m >=< a >
A cohort-wise measure then approximates the true mean physiological value.
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Figure 8.11: Data clustering over the first three PCA components. Pie charts show the
percentage of negative and positive subject in each cluster.
In the simplest longitudinal scheme
∆m = (at1 − at0) + δ(at1 − at0)
which becomes:1
∆m = ∆a+
√
(δat1)
2 + (δat0)
2 u ∆a+
√
2δa
In general, δa constitutes the limiting factor in all longitudinal analyses2.
Typically, one can estimate the measure error δa with a test-retest approach, where the
physiological change is assumed to be zero. Ethical considerations though do not allow
test-retest protocols with amyloid-PET. While the test-retest error cannot be assessed
without a dedicated experiment, we can still use a cross-sectional approach to rank dif-
ferent semi-quantification measures. In this case we can use a cohort-wise estimate of the
variance.
The idea is rather simple: suppose you have a set of identical objects and two different
tools to measure them, but you do not know the tools’ intrinsic error. You want to find
out which tool has the lowest error.
Under the hypothesis of independence among measures and tools versus objects, and if
you know that the objects are indeed identical, then the variance of all the measures made
with one tool is a proxy of the tools intrinsic error. This approach is best achieved in a
true test-retest experiment but we can still approximate the ”identical objects” condition
by population partitioning.
1Propagation of errors in a sum.
2In longitudinal analyses with multiple time points one can use a model (i.e. linear) to estimate the
rate of change. In this case the uncertainty on the rate can be smaller than δa
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Figure 8.12: Standard deviation of the normalized data (z-score) grouped by clusters
and semi-quantification method. Red line is the median, colored boxes are 1 standard
deviation of the points, lines are the 95% CL. Clusters are ordered by increasing amyloid
positivity.
Let us consider a set of amyloid quantifiers qj, j = 1..n and apply them to a population P
of m subjects. We get a matrix Qij i = 1..m, j = 1..n of measures. This matrix can also
be described in terms of its PCA components sk and let us take enough sk so that the
measure matrix is described up to a high explained variance (for instance 90%). We can
now cluster data using the sk principle components and divide subjects into C number
of clusters. By definition, cluster are more homogeneous than the whole population, that
is, subjects belonging to one cluster are more similar among themselves than they are to
subjects belonging to different clusters.
We can now compute the standard deviations of all measures q on the partitioned measure
matrix Q. We get a matrix of standard deviations Saj a = 1 : C, j = 1..n, that is Saj is
the standard deviation computed over the value set {Qij, i ∈ Ca}, that is computed over
the column j of Q where the rows belongs to the cluster Ca.
For two semi-quantification techniques (i = 1..2) applied to the same scan group and
under the hypothesis that the physiological variability and the semi-quantification are
independent, we can write
σ2mi = σ
2
a + σ
2
δai
We should now compare the two variances σ2m1 and σ
2
m2
. This time though we have limited
σa because of the clustering (although we cannot quantify it yet). Actually, if we have a
set of values for each technique (such as the regional information or paragraph 8.1), we
have to compare a set of σ too. In addition, as we assumed independence of physiological
variability and the semi-quantification, we can take all homogeneous cohorts and consider
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Figure 8.13: Overall distribution of the standard deviation (on normalized data). The
distribution merges all regional quantifications and clusters.
their variances together. In the end therefore, we can compare a whole set of variances
from one technique with another set of variances from another technique. The one which
score lower is the ”better” technique in terms of test/retest capabilities as it shows that
it has a significantly lower intrinsic variance when measured over the whole population.
We applied this reasoning to the Multicentric Pilot Dataset (MPD) to test the perfor-
mances of SUVr, ELBA and TDr. We remind that this is test does not imply a direct
measure of the test-retest error, rather, it can only rank methods on the smallest vari-
ance3. Still, as we could not apply the TDr to the ADNI dataset (as in paragraph 8.2.1)
we can at least assess the TDr potential in terms of intrinsic error by comparing it to the
other two methods on the same dataset.
8.3.1 Implementation and results
Data were clustered into three partitions (of 26, 48 and 73 elements respectively) using the
first three PCA components, which explain ≈ 85% of the total variance (figure 8.11). We
applied hierarchical clustering with Ward’s linkage, and these clusters roughly correspond
to negative, positive and borderline subjects (cluster 2, 1 and 3 respectively).
We constructed a measure matrix by juxtaposing the 51 quantifiers from each method,
resulting in a matrix of size 147 × 153 . As each method has its own value range, we
normalized the measure matrix into z-score in order to compare standard deviations. For
each cluster and for each method, we computed the standard deviation of the regional
3although it can be considered as a superior limit of the test-retest error.
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and global z-scored quantifiers, which amounts to 51 values per method and per cluster.
In total, each method is characterized by 51 (quantifiers per method) × 3 (clusters) = 153
standard deviation values.
Results are shown in figure 8.12 and 8.13. The overall distributions (shown in figure
8.13 both as histograms and box plots) clearly indicate the TDr as the method with the
lowest intrinsic error (p < 10−3) with respect to both ELBA and SUVr (ANOVA). The
test between ELBA and SUVr shows that ELBA is also significantly lower than SUVr
(p < 10−3). Incidentally, the results comparing ELBA and SUVr confirm the findings in
paragraph 8.2.1, where ELBA had a better consistency in a longitudinal analysis.
Data grouped by cluster and method show that TDr is consistent on all data while ELBA
and SUVr are both significantly different in clusters 1 and 3 versus cluster 2. This indicates
that the uncertainties in these two methods are biased by the amyloid load, so that our
assumption of independence of the error from the data is not verified.
Chapter 9
Beyond dichotomy
All semi-quantification methods and their variants proved sufficiently accurate when com-
pared to the negative / positive assessment, either provided by a single reader or in the
more complex multi-reader approach. Yet, if we limit the quantification information to
the simple dichotomic answer we find that it is hardly worth the analysis.
In a recent paper (Pontecorvo et al., 2017) authors complemented both expert and novice
readers with a SUVr-based semi-quantification software. The goal was to examine the
feasibility of quantitation to augment interpretation of PET amyloid imaging. They
found that augmentation of visual interpretation of PET amyloid images with quantitative
information (obtained using commercially available software packages) was significant,
raising the overall accuracy from 90.1% to 93.1% (p < 0.0001). Curiously though, they
also found that the use of quantitation did not reduce the accuracy of readers who were
already performing with above average accuracy on the visual read (a meagre result...),
and could improve the accuracy and confidence of some readers in clinically relevant cases
(a much better result!).
That is to say that, on one side, easy-to-read cases are finely assessed both by novice
and by expert readers, limiting the quantification tool to a confirmatory role. On the
other side, difficult-to-read scans cannot easily be trusted to a single implementation of
a semi-quantification software, due to all the known uncertainties in image treatment,
normative dataset and physiological peculiarity. Hence, there is little to gain with semi-
quantification when used only for confirmation of the binary assessment1.
We propose a paradigm shift that abandons the binary assessment in favor of a continuous
scale (rank), ranking scans form the most negative to the most positive. We understand
that this rank is but the tip of the iceberg, as a single value cannot possibly entail all the
subtle nuances and complex information found in a 3D image.
9.1 From binary reading to ranking
A dichotomous evaluation is appropriate in the assessment of amyloid accumulation in
cases where the presence or absence of Aβ is evident: in these patients this process has
either not yet begun or it has already reached a plateau. Due to the current use of
1An obvious exception though is in the analysis of large dataset, where the statistical approach is
central to the study.
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Figure 9.1: Examples of the link between the estimator Xˆ and the rank R. Left: PCA-
based weights with quantile normalization (Xˆ(p) and R(p)); right: constant weights with
z-score normalization (Xˆ(m) and R(m)). Each rank can also be normalized (R→ Rˆ, right
axis of each plot) on a standard range [0 − 100] to get a number independent from the
normative dataset size.
amyloid-PET in the diagnostic flowchart (see section 3.2), most patients should easily fall
into these categories.
Yet, clinical experience show that the number of difficult classifications is not negligible,
with an approximate figure of merit of ≈ 20% of all scans. These scans can be difficult to
interpret for a number of reasons: they can belong to subjects whose accumulation process
is still in progress; they can present confusing elements (i.e. bad quality); or there can be
structural and physiological reasons (such as the presence of significant local atrophy).
Whatever the reason, these scans are almost always very close to the cut-off value regard-
less ot the semi-quantification method. Therefore the dichotomous evaluation is “forced”
on them.
If we assume that technical issues and atrophy can be ruled out by appropriate proto-
cols and clinical investigation, we can concentrate onto those subjects which may indeed
present a general borderline amyloid load. Because future therapies are likely aimed
at counteracting the accumulation process, these cases are also most interesting from a
clinical point of view.
9.2 Integrating estimators
Overcoming the distinction into two categories can be achieved by finding criteria for
scans subdivision into several classes, or by a method for ordering them. The strategy is
the integration of all semi-quantitative values.
The idea here is that each method (SUVr, ELBA and TDr) is a proxy measure of the
”true” amyloid load. As each method is based on a different approach – reference-tissue
intensity for SUVr, geometric properties for ELBA and delayed-ROI intensity ratio for
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Figure 9.2: Data matrices: raw (xij, left), z-score normalized (zij, center) and quantiled-
normalized (qij, right).
TDr – we can assume that they behave coherently with the amyloid load (see the general
correlation results in section 7.2) but they are uncorrelated with respect to the intrinsic
/ data treatment errors.
As a rough proof of this, let us briefly analyze the pattern of the residuals from section
7.2, figure 7.9. We tested whether residuals correlate with any of the quantifiers and
whether residuals are normally distributed and we found no significant correlation and
no significant deviation from normality on all residuals and on all methods comparison.
Thus is it reasonable to use all three semi-quantification methods to provide a single and
more robust estimate.
According to the sample parcellation introduced in paragraph 8.1, each of the three meth-
ods now delivers 51 variables (from the 25 contralateral regions plus the whole brain).
Obviously, each 51× 3 variables could be used as a ranking value but we are now looking
to obtain a more robust result.
Out of the infinite ways to combine several observations, we chose the linear combination
(i.e.weighted average). The general functional form is therefore
Xˆ
(k)
i =
N∑
j=1
xij w
(k)
j (9.1)
Where N is the number of variables (153 in our case) and i = 1..S the number of subjects.
The subscript (k) indicates possible ways of choosing the weights. If we order Xˆ(k) from
the minimum to maximum value, we define the rank R
(k)
i as the ordered position of subject
i in Xˆ(k) (where the weights are chosen with criteria (k)). Therefore while Xˆ
(k)
i assume
real values, R
(k)
i assume integer values (figure 9.1).
Some typical choices for the weights can range from a constant value (i.e. the simple
mean) to the maximum variance methods (i.e. PCA).
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Figure 9.3: Comparison among ranks versus weight choice method (constant, correlation,
PCA) and normalization (z-score, quantile). d is the rank distance (equation 9.4) with
respect to the “quantile-PCA” rank.
9.2.1 Weights determination
The first and easiest choice for w
(k)
j is the constant, that is w
(m)
j = 1/N , j = 1, . . . , N ,
hence Xˆ(m) is the aritmetic mean.
Other possible choices can take into consideration the AUC on the normative dataset, or,
if we wish to be independent from it, we could exploit the correlation among quantifiers
(columns of the matrix xij). In facts, it is reasonable to assume that high correlation
among quantifiers is a good indication of their ability to estimate the amyloid load.
So the second tentative weight selection is proportional to the correlation among quan-
tifiers. The intent is that correlated quantifiers are assigned a higher weight than those
poorly correlated. This is achieved by averaging the correlation matrix ρij
ρjk =
S∑
i=1
(
xij − 1
S
S∑
i′=1
xi′j
) (
xik − 1
S
S∑
i′=1
xi′k
)
√
S∑
i=1
(
xij − 1
S
S∑
i′=1
xi′j
)2√ S∑
i=1
(
xik − 1
S
S∑
i′=1
xi′k
)2 (9.2)
over its columns, so that
w
(c)
j = ρ¯j =
1
N
N∑
k=1
ρjk (9.3)
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Figure 9.4: Comparison between the ranks due to four quantifiers (columns of the
measure matrix xij) versus the reference rank (PCA over the quantile-normalized matrix).
d is the rank distance (equation 9.4) with respect to the reference rank.
(the subscript (c) here stands for correlation, as (m) stands for mean).
Finally, we can use the principle components analysis. In this case we only consider the
first component (largest variance explained and projection onto the first autovector α1j)
and w
(p)
j = α1j.
As quantifiers come from three different methods, it can be necessary to normalize them
before summation. Range normalization can be achieved in several ways. We studies the
effect of a linear (z-score, zij)
zij =
xij −Xj
σj
and a non-linear normalization (quantiles, qij), implicitly defined as.
xij =
∫ qij
−∞
pdfj(n)dn
where pdf(n) is the probability density function of the entire normative dataset2. The lat-
ter transformation assumes that the normative subjects be the same for all methods. See
figure 9.2 for a graphical representation of the measure matrix xij and its normalizations
zij and qij.
The three weights choices are applied on the normalized quantifiers (zij or qij), giving out
6 possible outcomes.
Now the question rises on how to tell which weight choice and quantifier normalization is
preferrable. An obvious solution would be to use Xˆ as a classifier and look for a rank that
maximizes a metric over the ground truth of confirmed negative/positive labels (i.e. AUC,
accuracy, etc). This approach though is not very informative as any random permutation
of subjects within the same class does not alter the classification metric.
To find the “best” rank therefore we need to resort to another kind of metric. To help
us we define a distance d(R(1), R(2)) between two ranks R(1) and R(2) as the number of
permutations that we need to make R(1) = R(2), multiplied by the distance between each
2Alternatively we can write
xij = cdfj(qij)→ qij = icdfj(xij)
that is with the cumulative distribution function (cdf) and its inverse (icdf)
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two elements that have been permuted (we remind that R(k) assume integer values):
d(R(1), R(2)) =
1
2
S∑
1
|R(1) −R(2)| (9.4)
where S is the number of subjects in our normative dataset. For instance, if R(1) =
1..n..n + l..S and R(2) = 1..n + l..n..S, then d(R(1), R(2)) = 1/2(| − l| + |l|) = l. We can
visually compare ranks as in figure 9.5, where we plot R(1) = 1..3..5..10 versus R(2) =
1..5..3..10 with dots. We can clearly see the exchange in the position of elements #3 and
#5, as well as the rank distance d = 2.
Figure 9.5: Sample visualization comparing
two ranks.
We now examine the six ranks (three
weight methods by two normalizations) in
figure 9.3, where the PCA/quantile-based
rank was used as reference for the plot.
We note that the choice of the weights
and the quantifier normalization have a
rather small influence on the rank, influ-
ence which is mostly limited to elements
permutation in the extreme positions (d is
rather small).
We remark that rankings do not use any
ground truth label (neg / pos), they are
entirely determined by the raw quantifier
values (save for an intensity normalization
based on the overall normative dataset).
We now need to determine whether there
is one (or more) rank that is preferrable
to others, given the fact that all ranking
(and even some single quantifiers) score an
AUC ≈ 1 (and an accuracy = 0.97) on the
binary reading. In absence of a finer visual
grading, there is virtually no way to search for and validate a rank so that it represents
a scale from the most negative to the most positive subject.
For instance, let us visually compare a rank of choice and those coming from some of the
single quantifiers which score the same accuracy over the visual assessment. The rank of
choice is R(p), which comes from the ordered indexes of Xˆ(p) (first component of the PCA
with quantile-based normalization). The other ranks come from the ordered indexes of
some quantifiers such as xi 52 and xi 109, figure 9.4.
We can see that the distance among the single quantifiers and the reference rank is larger
than that between all the other rankings in figure 9.3, and yet all these score AUC ≈ 1.
This is due to the fact that all these selections do not mix scans between classes (neg /
pos) so that there is no way to tell which one is “better” than the other from a simple
dichotomic assessment.
While it is reasonable to assume that single quantifiers on small ROIs are more prone to
errors than a value built on all available information, we need a more robust criteria to
decide it.
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9.3 One-dimensional transition model
To help identifying a possible alternative criteria for ranks, we built a simple one-
dimensional, 2-classes model (low / high) having S values taken from a sigmoid function
plus some added Gaussian noise. A pictorial representation is in figure 9.6. In this simple
construct, noiseless elements below 0.5 are ”negative” and above 0.5 are ”positive” (the
Gaussian noise then mixes them up a little). We suppose to know the ”true” ordering
R(1) of these S elements, which is the one represented in the top left plot of figure 9.6.
Following the same reasoning of paragraph 9.2.1 we can: (a) randomly permute the
elements in each class (without mixing between classes, ordering R(2)) and (b) randomly
permute all elements, with class mixing (ordering R(3)). The corresponding permutation
plots are shown in figure 9.6, rightmost plots.
Now we compute the moving standard deviation (msd), that is the standard deviation
of a moving subset of s contiguous elements, having chosen s to be comparable to the
transition width of the sigmoid.
In the ordered system (R(1)), the standard deviation for each moving subset s is dominated
by the Gaussian noise. As soon as the moving subset approaches the transition, the “true”
ordering guarantees the smoothest transition (low values of the msd).
With the R(2) rank instead, the msd assumes approximately the same values as before
when s is at the extreme of the rank. When approaching the transition though (now
sharper) it has much higher values, resulting in an overall distribution with a higher
mean (figure 9.6, center). Finally, With the R(3) rank, the msd is at the highest, as each
moving subset s contain both low and high values.
The distribution of the msd values, computed over moving subsets of the whole population,
reflects the permutation of the rank and, in this simple 1-dimensional model, its average
is minimum for the “true” rank.
9.4 Degree of order
We can apply the same concept to our data, where an approximate equivalent of the
standard deviation of the one-dimensional model is the degree of order (DO).
The DO is a value that is used to characterize a system dynamic and it is usually defined
as a measure of the internal correlation of a system (Chandler, 1987). In general, when a
system undergoes a change either due to internal reordering or due to external stresses,
this often reflects into the DO. During a transition, for instance, the number of significant
components is reduced (Gorban et al., 2010).
A synthetic measure can be built using correlation among the variables that describe the
system. A typical implementation uses principle component analysis (Gorban et al., 2010)
and its derivative. For instance, some authors use the variance explained by the first n
autovectors of the PCA (Gorban et al., 2010; Jolliffe, 1986).
An exhaustive discussion of the DO and its implementation is out of the scope of this
work. Here we shall use an operative definition of the DO (denoted by the symbol Ω) as
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Figure 9.6: Simple 1-dimensional transition model. Colors show the two classes. Top
plots: data in the “true” order R(1) (left), distribution of the moving standard deviation
(center), rank comparison with respect to R(1) (right, in this case it is trivial). Center
plots: data mixed within classes only (order R(2)) (left), distribution of the moving stan-
dard deviation due to R(2) now compared with that of R(1) (center), rank comparison
with respect to R(1) (right, no between-classes mix). Bottom plots: data mixed with a
random order (R(3), left), comparison of the three distributions of the moving standard
deviation (center), rank comparison with respect to R(1) (right).
follows:
Ω =
α˜1∑S
j=2 α˜j
(9.5)
where α˜j is the variance explained by the j-th PCA component (
∑S
j=1 α˜j = 1).
In a completely random system with N degrees of freedom, the variance explained is
approximately shared by all components so that Ω ≈ 1/N. Viceversa, a system where
one or more degrees of freedom exhibit large variances, the first component will tend to
capture this range and Ω 1. (see figure 9.7 for a simple example).
In a recent work by Pagani et al. (2016), the DO was used to quantify the loss of coherence
within clinical groups measured by FDG-PET. Inspired by this work, we apply the DO
to the measure matrix xij and we study the ordering effect of the various ranks.
Similarly to the simple approach in paragraph 9.3, we compare different ranks: one com-
pletely random, some based on a single quantifier (see figure 9.4) and the R(p). As we
do not know the real transition width, the moving average is carried out over several sets
ranging from 8 subjects to 20 subjects.
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Figure 9.7: Simple comparison of two systems with two degrees of freedoms. System
x (left) is a random system, system y (right) has some correlation. The two PCA vec-
tors length (colored arrows) are proportional to the variance explained by the respective
components. The degrees of order are Ω = 1.3 and Ω = 6.1 respectively.
Results are shown in figure 9.8, where the dots are the Ω values for all moving sampling
(that is a sliding subset of s subjects that covers the entire range, and s = 8..20). Here
too, we find that the random rank has the maximum variance because in each subset s we
can find subjects from different classes. More interestingly though, the ranking due to a
single matrix column behaves similarly to the intra-class permutation rank in the simple
1-dimensional model. We conclude therefore that the PCA-quantile-based rank R(p) is
the relative best choice. At this point we cannot conclude that R(p) is the absolute best
rank, but only that it performs best (in terms of Ω distribution) with respect to all other
tested choices.
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Figure 9.8: Degree of Order distribution for different rankings of the measure matrix.
Chapter 10
Clinical impact
The analyses and methods presented in this work were developed to fulfill the lack of
reliable tools for quantitative analyses in the everyday clinical evaluations of amyloid
PET. We believe that a more sophisticated approach to amyloid PET evaluation can
benefits clinicians in many ways, both in standard practice and in research.
The application shown here was prepared on the 18F-florbetapir tracer (Amivid), although
a completely analogous tool can be given on all tracers, provided we get a proper normative
dataset.
10.1 Summary plots
We have now the opportunity to summarize all the analyses into a single report that can
be used in clinics.
The idea is to present each semi-quantification method and their combination into a single
rank within a unified report that can be easily accessed by clinicians.
We designed a simple report that is delivered for each patient and includes the amyloid
rank plot and all the three semi-quantification assessment with both regional and whole
brain values. Numbers and the respective cut-offs are provided both raw and within the
normative dataset cumulative probabilities.
Rank is computed with the PCA and quantile normalization. First we introduce the rank
plot: this plot simply shows the normalized rank of a new subject onto the normative
Rˆ − Xˆ curve (figure 10.1). The analysis procedure first computes the 51 quantifiers for
all the three methods (SUVr, ELBA and TDr) and combine them into a single quantifier
Xˆ, which is then mapped into the rank Rˆ by means of the normative data curve. This
plot then is the synthesis of all previous analyses and delivers the most robust quantifier.
Then we have the single methods’ local probability plot, which needs a bit more explana-
tion. The main feature of this plot is the cumulative probability curve: this curve consists
of the sum of two cumulative probability functions, one for the negative and one for the
positive normative data. The curve formula is:
y =
∫ x
−∞
pdf (−) +
∫ x
−∞
pdf (+) − 1 =
∫ x
−∞
pdf (+) −
∫ ∞
x
pdf (−) (10.1)
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Figure 10.1: Rank plot linking the quantifier weighted sum Xˆ(p) with the normalized rank
Rˆ(p). White dots are the position of the normative data, blue thick line is the non-linear
fit, shadowed area is the 95% CL on the fit. The new data at Xˆ(p) = −2.5 is mapped
into a normalized rank Rˆ(p) = 28.4. Rank CL (within square brackets) are estimated by
intersecting the new data with the confidence limits from the normative data fit.
where pdf (−) and pdf (+) are the probability distribution functions of the negative and
positive subjects in the normative dataset. The pdfs are separately computed for each
quantifier of the measure matrix xij.
Figure 10.3 graphically shows a sample cumulative probability curve. This visualization
allows to immediately grasp the probability of belonging to the positive and negative
group. The curve crosses zero at a value xˆ when the probability of finding a negative
normative subjects with quantifier value xn > xˆ (
∫∞
xˆ
pdf (−)) is the same as finding a
positive normative subject with quantifier xp < xˆ (
∫ xˆ
−∞ pdf
(+)). In other words, the
negative portion of the curve indicates quantifier values for which the probability of finding
a negative subject is higher than that of finding a positive subject.
Each quantifier in the measure matrix xij is used to draw a cumulative probability curve
and this is the basis for the probability plot, which shows the detailed analysis for each
method and each parcellation Pk (figure 10.2).
This plot also shows the position of a subject on the normative probability curves. The
subject quantifiers are places on each curve, which have been shifted so that the all their
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Figure 10.2: Placement of a subject’s quantifiers (single method) on the normative
cumulative probability curves.
cut-offs are at the same value than the whole-brain one. On the y-left axix we have the
difference between the cdf of the negative and the positive scans in the normative dataset
(equation 10.1).
The subject’s quantifiers are plotted as gray dots on the curves, according to each own’s
value. The dot size is proportional to the AUC of the parcellation region Pk (see paragraph
8.1 and figures 8.2, 8.3 and 8.5) so that parcellation with less significance are visually
unobtrusive. The regional markers are also complemented with a green and a red dot,
showing the most negative and positive regions among those which perform with AUC>
0.95 on the normative dataset.
The whole brain quantifier is drawn on a thicker probability line with a white square
marker and it is complemented by a red vertical and horizontal lines. The vertical line
visually enhance the whole-brain quantifier value on the x axis, while the horizontal line
shows ±1 standard deviation computed on all Pk quantifiers with respect to the whole
brain.
On the y-right axis we plot a bar representing the fraction of regional quantifiers which
lye below / above the equal cumulative probability line (depending on the position of
the whole brain marker). It is labeled “neg / pos confidence” because it measures the
consistency within regional quantifiers.
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10.2 The amyloid-PET quantification report
Figure 10.3: Cumulative probability curve
example. Boxplots shows the negative and
positive normative data distribution over a
given quantifier. Cumulative probability
function of the negative and positive distri-
butions (blue and red curve, the blue curve is
shifted by −1). The yellow curve is described
by equation 10.1
A typical report is shown in figure 10.4. It
consists of several parts:
• patient name and age, taken from the
DICOM files;
• the rank plot (figure 10.1), showing
the patient rank with respect to the
normative dataset;
• the regional semi-quantification ver-
sus probability curve for each method
(figure 10.2)
• the most negative and most posi-
tive regions among those with high
performance (AUC on the normative
dataset > 0.95)
To clarify the reading, each curves plot
also shows two probabilities: the probabil-
ity
∫∞
x˜
pdf (−) of finding a negative norma-
tive subject with whole-brain score greater
then the subject score x˜; the probability∫ x˜
−∞ pdf
(+) of finding a positive normative
subject with whole-brain score lower then
the subject score x˜. We can also read the
subject’s whole brain score with the star-
dard deviation computed on the regional
scores, the cut-off and the numerical value
of the confidence (gray bar on the right y axis in figure 10.2).
Next to each curve probability plot we also show the method’s take on the most negative
and most positive region (green and red region), which correspond to the green and red
dot in the probability plot. Sagittal, coronal and axial sections are visualized on the
subject’s scan in the MNI space, and centered on the relevant parcellation centroid.
The report is complemented with a disclaimer, a brief legend and a summary table with
the normative dataset demographics.
We have made the analysis completely automatic. Currently, we provide a web site
(https://nextmr01.ge.infn.it/myPET/) where selected and registered users (typically
nuclear medicine physicians) can access the analysis and run it remotely. This was nec-
essary because the average computer which is usually present in hospitals cannot run
the whole analysis in a reasonable time. The analysis pipeline is therefore hosted on a
dedicated computing infrastructure at the National Institute for Nuclear Physics (INFN),
which provides computing power adequate for the task.
The typical processing time is ≈ 20 minutes. At the end of the process all relevant and
confidential data are deleted from the system, while the registered clinician receives the
amyloid report vie email.
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10.3 Clinical research and borderline cases
Outside the general clinical goal to tell negative and positive scans, we enter the clinical
research framework where we are interested in less obvious evaluations. Borderline scans
can occur for several reasons: “technical” reasons include patients with marked cere-
bral atrophy, scan of not optimal technical quality (movement, low counting statistics,
noisy images or too smoothed), reader experience (inter-observer agreement), modality of
analysis (visual, semiquantitative ...).
Still, there can be “true” borderline cases, that is patients with borderline deposits of
amyloid plaques. There are relatively few works in literature on these cases although we
know that borderline deposits of amyloid plaques have indeed been observed (Sojkova
et al., 2011).
A search was carried out on PubMed to look for explanatory works on amyloid borderline
cases, using a variable combination of keywords: “limitation Amyloid PET”; “Borderline
SUVR amyloid imaging”; “Unclear cases / uncertain results amyloid PET”; “Unclear
visual assessment amyloid PET”; “Difficult amyloid scan”; “Uncertain florbetapir scan”;
“Prognostic value amyloid PET / imaging”; “Stratification of risk amyloid PET Very few
relevant articles were found, except perhape for for Mormino et al. (2012), although his
work places the accent on the presence of dubious scans, without providing hypotheses or
solutions on what could be their meaning or definitions.
These borderline subjects are likely at the beginning of the amyloid accumulation process,
and will probably continue the neurodegenerative path; they are therefore the ideal target
for future therapies. The dichotomical assessment is inadequate in these cases and it is not
trivial to find operative definitions of borderline cases (Baker et al., 2017; Mormino et al.,
2012; Fleisher et al., 2011). In addition, one cannot rely on simple numerical estimates
either, as SUVr cut-offs on the same tracer vary among studies on a considerable range
(from 1,06 to 1,80).
Our ranking approach was then used for a very exploratory study on a small cohort of
mildly negative and borderline patients, where the uptake quantification (and hence the
inclusion criteria) was not defines by SUVr values, but by a range in the normalized rank.
We selected outpatients from a naturalistic population who were examined at the S.
Martino Hospital in Genoa, Italy (HSM, the same center which also contributed to the
Multicentri pilot Dataset). All patients had an amyloid PET scan following the diagnostic
pathway outlined in paragraph 3.2.
Out of these patients, we selected 12 who were found to be intermediate, that is within
a normalized rank Rˆ ∈ [30 − 70]. We than selected a set of clinical, neuropsychological
and neuroimaging medical report on MRI, FDG-PET and amyloid-PET. The idea is to
try profile these patients, looking for possible clues to their etiology and – perhaps – their
prognosis.
The high heterogeneity in clinical data collection and assessment did not allow a thorough
dataset collection and we had to select and sift through several possible choices, in order
to keep the dataset as complete as possible. Out of all clinical examinations we selected
a subset that was common to all patients and we operated a categorization of all clinical
variable in order to enhance internal normalization and to provide a solid base for the
rank analysis. A sample of the clinical data gathered is in table 10.1. This is only a small
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subset of the data that were gathered; for brevity, not all clinical information are shown.
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(a) (b)
(c) (d)
Figure 10.4: The amyloid-PET report. (a) patient data, rank plot, SUVr probability curve
and its most significant regions; (b) ELBA and TDr probability curves and most significant
regions; (c) legend; (d) disclaimer, references and normative dataset demographics.
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Figure 10.5: Preliminary results on a small subset of borderline patient. Medical report
on amyloid PET included regional (Parietal, Frontal Temporal and Precuneus) with the
qualifiers B,L,R,N (bilateral,left,right,normal); Neuropsychological assessment included
Trail making test (A and B), and Constructive Praxia – simple copy with semantic cor-
rection.
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Table 10.2: Linear model on borderline and negative cases.
Estimate Standard Error t-Statistics p-Value
(Intercept) -14.087 25.46 -0.55 0.587
Hypertension -13.587 7.22 -1.88 0.077
Trail Making Test (A) 0.263 0.10 2.42 0.026
Constr. praxia (simple copy) corrected 5.024 2.55 1.96 0.065
These patients were compared to another small set of 13 decidedly negative patients (i.e.
Rˆ ∈ [0−30]) that were enrolled in the same center and under the same inclusion/exclusion
conditions (that is symptomatic outpatients with uncertain diagnosis but with AD as
possible outcome). Therefore these are not controls, nor normal aging subjects. Rather,
they are totally similar to the borderline patients from the pre-amyloid-scan point of view,
save for the fact that they tested negative to the amyloid PET (and therefore AD was
excluded as diagnosis).
Once the target and reference population were defined, and the clinical data gathered, we
proceeded with two simple analysis: (a) each covariate is separately checked against the
rank: if the covariate is a continuous variable we used Pearson correlation, for categorical
variables we used the ANOVA test; (b) we built a general linear model to predict the
rank: the idea is to use a mixed regression for categorical data and continuous variables,
looking for predictors with high significance.
Preliminary results are in figure 10.5. We fixed the p value for the ANOVA (categorical
covariates) and correlation (continuous covariates) to p = 0.05. The only significant
neuroimaging covariates come from the Nuclear Medicine report of the amyloid PET (an
expected result). No MRI or FDG-PET related information from the clinical report had
any significant correlation; this obviously do not exclude more subtle relationships (i.e.
by direct analysis of the neuroimages), it only states at – at this level of details – the
amyloid-PET quantification is not related to other neuroimaging techniques, (it provides
independent information).
The second preliminary result is the linear model (table 10.2). Due to the dataset lack
of completeness, the model statistics are the following: 21 observations, 17 error degrees
of freedom, estimated Dispersion: 248, F-statistic vs. constant model: 6.72, (p-value
= 0.00343). The Anticoagulant feature is not present because it correlates with the
Hypertension.
These preliminary analyses indicate that further studies on borderline patients are war-
ranted, and that we can probably profile them both with thorough neuropsychological
tests and with detailed anamnesis.
Due to the very limited number of patients, the single-center provenance and the lack of
a proper common protocol in the clinical data, we remark once again that the borderline
patient analysis is exploratory at best, and that there is no clinical conclusion to draw
from this results as yet.
Chapter 11
Discussion
This work deals with the clinical and methodological use of amyloid-PET. We have studied
in particular the problem of quantification and its relationship with clinical assessment,
visual evaluation and longitudinal analysis. We have also developed a simple and robust
quantifier derived from all available and validated methods.
This discussion will focus primarily on the ELBA method, which was studied more thor-
oughly and validated on an extensive dataset. Then we shall discuss the TDr, its relation-
ship with SUVr and ELBa and the advanced topics of regional and longitudinal analysis.
Finally we discuss the ranking and its potential.
11.1 ELBA validation
The proposed analysis shows that it is feasible to construct a semi-quantification method
on amyloid-PET images without relying on counts-ratio approaches. The ELBA method
shows good performance versus the dichotomic visual assessment and has ranking char-
acteristics, proven both on cohort-based and longitudinal analyses.
From a methodological point of view, both SUVr-based and ELBA approaches require
image registration techniques (spatial normalization), although the lack of small cortical
ROIs in ELBA renders the registration process and the template choice less demanding.
ELBA tries to mimic the human visual process, in that it captures information on global
contrast and intensity distribution rather than weighing intensity in predefined regions.
While further tests are necessary – particularly on all other major PET tracers and with
histologically validated scans – it is worth noting that this process delivers comparable (if
not slightly better) information in terms of semi-quantification, classification and ranking,
with respect of the widely used SUVr methods.
11.1.1 Blind and open phase performance
Expert readers were concordant and confident in reaching a diagnosis (positive or negative)
on 403 scans (82.6%), without the influence of clinical information and other imaging data.
This finding confirms that a trained reader can safely rely on his/her experience on over
80% of images, when evaluating by means of visual analysis.
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As a second point, the five expert readers were not able to give a concordant diagnosis
(i.e., amyloidosis present/absent) in 22 (4.5%) images and in 63 (12.9%) more images
at least some of them declared that the initial assessment was unclear (i.e., doubtful).
Interestingly, uncertain-tagged scans were mostly located in the negative domain whereas
conflicting scans were evenly placed around the cut-off. As a consequence, looking at the
fraction of uncertain and contrasting labels vs clinical cohort (blind session, table 7.2) we
find that for cognitively normal subjects and EMCI it is 23% and 21% respectively, versus
a 11% found in MCI and LMCI (AD has 0%).
Overall, these 85 (17.4%) scans may represent the borderline scans where a quantification
approach can help in reaching a definite diagnosis. This fraction of scans is polled from
61 subjects and could derive both from healthy subjects or mainly early MCI patients in
a stage when Aβ is accumulating in the brain but still in a limited amount (Villemagne
et al., 2013; Jack et al., 2013), thus leading to difficult reading. In facts, they belonged
to NS (22), EMCI (27), MCI (4) and LMCI (8).
When the experts were aided by the closest negative and positive images - as yielded by
the ELBA output - the 22 conflicting cases and 63 uncertain were solved, which is a non
trivial aid this automatic system can provide even to expert readers. We have not tested
the potential aid ELBA can give to less experienced readers but it should be intuitively
higher.
A substantial number (about 19%) of healthy subjects had a positive score, although
the positivity fraction is mainly ascribed to the elderly (> 70 years) ones, on a par
with literature findings. Also, a few patients with AD had a normal score, which is in
keeping with literature works (Johnson et al., 2013b) and raising the possibility of wrong
clinical diagnosis (ADNI subjects do not have pathological confirmation), patients with
discrepant normal amyloid-PET scan but abnormal Aβ1−42 levels in cerebrospinal fluid
(Landau et al., 2013) or, alternatively, of patients with suspected non Alzheimer pathology
(SNAP, Jack (2014)).
In the middle, MCI subjects in progressive stages of cognitive impairment were roughly
halved between positive and negative scans which highlights the presence of causes of MCI
(such as frontotemporal lobar degeneration or vascular cognitive impairment) other than
AD, and possibly of SNAP. Ranking based on the overall amyloid burden is also apparent
and it is a benefit of the method, as the average ELBA score progressively increases from
healthy subjects to patients with AD.
11.1.2 Comparison with SUVr-based methods
The performance of both approaches are very similar, with a modest but statistically
significant edge in favour of ELBA. The optimized SUVr cut-off (=1.23 and based on
the visual assessment) is higher than the values typically considered in literature for this
ligand (1.10 - 1.14, Johnson et al. (2013b); Hutton et al. (2013); Camus et al. (2012)) but
it agrees with other works (e.g. Mattsson et al. (2014)), where their cut-off value (1.24)
was obtained by AUC optimization.
Table 7.1b and 7.2 summarizes the binary classification (ELBA and SUVr) versus the
visual assessment in both blind and open session. The comparison to cortico-cerebellar
SUVr in the cases where both methods agree shows that SUVr values are not alone in
providing good classification relative to visual assessment, and that and alternative and
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independent approach can enrich the information obtainable from the PET scan.
Although the ensemble on which the two methods disagree is limited to a small number
of subjects (quadrants for which ELBA / SUVr are pos/neg and neg/pos), the apparent
trend is that subjects negative to the visual assessment are likely to be considered negative
by ELBA (although not far from its cut-off) but are considered positive for SUVr. This
suggests that whole-brain amyloid burden evaluation is more concordant with respect to
a visual read than (small) ROI-based quantification on borderline cases. When keeping
the blind visual assessment as reference (that is using only the N and P set, table 7.2)
this distinction is even more pronounced: 15 out of 19 cases agree with ELBA versus 4
out of 19 for SUVr.
11.1.3 Comparison with CSF Aβ42
The comparison between ELBA score and CSF Aβ42 assay yielded a satisfactory agree-
ment with 90.6% concordance, in the same range (Landau et al., 2016) or even a bit higher
(Landau et al., 2013; Zwan et al., 2016) than those achieved in previous works using the
SUVr approach. Discrepancies (7.5%) were mostly found in patients with abnormal Aβ42
levels and a normal ELBA score. Such a limited discrepancy may be explained with
the notion that decreased Aβ42 reduction in CSF can precede brain amyloid deposition
(Palmqvist et al., 2016).
11.1.4 Clinical follow-up
Results shown in figure 7.10 suggest a cautionary attitude when using clinical evaluation
(even at follow-up visits) as gold standard. For instance, the lack of amyloid markers – as
evidenced by both CSF and PET analysis – is virtually incompatible with the diagnosis
/conversion to AD. It has recently been shown that a small but non-trivial part of AD
patients of the ADNI population shares a negative Florbetapir scan (Landau et al., 2016).
These Florbetapir negative patients would have a variety of clinical and neurodegeneration
biomarker features distinct from Florbetapir positive patients, suggesting that one or more
non-AD etiologies – such as cerebrovascular disease and SNAP – may be the main cause
of their cognitive deficit, mimicking AD.
On the other hand, MCI who reverted to NS condition may still have a negative or
borderline amyloid PET burden; among them an occasional patient may show abnormally
low levels of CSF Aβ42 and might theoretically become Florbetapir positive in the future
due to the earlier CSF positivity (Palmqvist et al., 2016).
11.1.5 Image quality issues
A non negligible fraction of scans (60 out of 504) were flagged as ”sub-optimal quality”
by at least one reader, and 37 were flagged so by all readers (a sample image is provided
in figure 6.1). This flag did not imply the impossibility of visual assessment, it meant
though that - within the boundary of the readers clinical experience - they deemed that
their evaluation was made more difficult by the image quality.
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Indeed, the apparent higher performance of the intensity feature C versus the geometric
feature G is actually incidental for this study, as scans provenance and quality are so
heterogeneous. In another study (unpublished) where data came from a single center,
we observed no significant performance difference between the intensity and geometric
feature.
The number of flagged scans is rather relevant, given the cost of the ligand and radiation
exposure to the patient. The peculiar relevance of image quality and resolution in these
investigations is most notable when dealing with difficult cases, as it is with those subjects
affected by significant gray matter atrophy. In addition, the relationship between flagged
scans and the blind phase uncertain label suggest that diagnostic errors are more likely
to be made on amyloid-negative subjects.
This highlights the need of procedural guidelines which underline the importance of spatial
resolution, partial volume effect correction, and the general minimization of acquisition
nuisances; all to be addressed in the official nuclear medicine societies guidelines on ac-
quisition protocols.
The general call to quality and consistency in nuclear medicine imaging peaks in longi-
tudinal studies. Considering the absolute value of the residuals || on the 16 subjects
with three scans and dividing them into two batches – the first one consisting of those
subjects acquired on the same site and scanner (nsame = 11) and a second one consisting
of those who had at least one scan taken with a different system (ndiff = 5) – we find
|same| = 0.04 ± 0.02 and |diff | = 0.14 ± 0.07. Although the modest number of samples
excludes a definite statement, the influence of scan consistency (both within and among
different sites) should be at least considered as a nuisance in the rather large spread found
in the evaluation of the ASC. For the same reason, we suggest a minimum of three scans
to attempt a reasonable estimation of the annualized score change, unless image quality
and consistency can be guaranteed (and possibly quantified).
11.2 TDr validation
We have shown that it is possible to define a SUVr-like analysis with no predefined uptake
and reference ROIs. The TDr method shows excellent performance versus the dichotomic
visual assessment and - similarly to ELBA - it has ranking characteristics.
From a mehodological point of view, TDr requires an additional spatial normalization
steps (to match the early scan onto the late) although the lack of predefined ROIs relax
the requirements on the registration onto the MNI space.
TDr takes the SUV ratio to a more refined level while maintaining the mathematical
simplicity of a ratio between average counts, thus avoiding the non trivial computing
steps required by ELBA.
On the same line of TDr, we should also mention the work of Cecchin et al. (2017) as
an excellent example of SUVr refinement. In order to improve the stability and therefore
the clinical applicability of the SUVr, the authors have developed a method based on the
integration of early late scan, plus the volumetric MRI of the subject. This multimodal
approach was able to correct the atrophy and dependence on regional CBF, both typical
bias for standard semi-quantification methods. Once more, this example indicates that
the problem of semi-quantification is far from being resolved and that new and improved
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procedures are needed.
11.2.1 Dataset issues
The mere fact that two scans per patient needs to be acquired, makes the TDr more
difficult to validate on existing and public dataset.
TDr was validated on a multicentric dataset and on a single tracer. All limitations
and discussions due to these conditions are the same as those just stated for the ELBA
method. The Multicentric Pilot Dataset though is much less refined than the ADNI,
even when limiting the considerations to the amyloid information alone. For instance, the
MPD did not provide any CSF measurements, and not enough clinical data nor follow-up
information to be used in validation as the ADNI dataset was used with ELBA.
We should remark though that the introduction of early scans is becoming more and more
popular for it is believed to be a reliable proxy to CBF and even FDG-PET (Ottoy et al.,
2017; Rostomian et al., 2011; Chen et al., 2015). Besides, the acquisition of an early
scan poses little inconvenience on the patient and on the scanner management. We have
therefore hope that more data will be available with two scans per subject, that we shall
use to consolidate the validation procedure.
The excellent agreement with the visual assessment is a necessary but not sufficient con-
dition to the proper TDr validation: first, the binary evaluations were not discussed in an
open session (as in ELBA) and they were given by unevenly trained personnel; second, the
inclusion/exclusion criteria were not stated or agreed before the creation and utilization
of this dataset.
The rather large heterogeneity in the patients demographics and the lack of a pre-study
agreement on scan quality related issues are probably responsible for the uneven response
of TDr on the Geneva patients shown in figure 7.8.
11.2.2 Comparison with SUVr and ELBA
The main result for TDr is the good agreement and correlation with the other two vali-
dated methods. Results in figure 7.9 clearly indicate that the TDr measures the amyloid
load at least with the same accuracy as SUVr and ELBA. When also considering the lack
of correlation in the residual analysis (paragraph 9.2), we conclude that TDr is indeed
another independent method.
As TDr is mathematically similar to SUVr (a ratio between two uptakes, averaged over
some ROI), one would expect a closer relationship with it. Instead, we find TDr to be
much more related to ELBA, both as correlation on the whole population and on the
separate negative and positive subjects. This latter consideration is very important as it
shows the ranking potential of TDr (and ELBA).
In addition, the intra-class correlation between TDr and ELBA impacts not only the TDR
validation, but also the pathophysiological implications. It confirms that the transition
between the negative and positive state is neither abrupt nor untraceable and that the
concept of borderline scans is actually not a mere technical nuisance.
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11.3 Longitudinal evaluation
The actual longitudinal experiment could be carried out on the ADNI dataset and with
ELBA and SUVr only.
The fitted model in paragraph 8.2.1 is qualitatively comparable to that shown by (Ville-
magne et al., 2013) albeit using a much shorter observation time (24 months), with a
different ligand and on a larger pool of PET scanners. The shorter follow-up time could
also explain why our findings on the SUVr longitudinal analysis exhibits a larger vari-
ability than that shown by (Villemagne et al., 2013). The ASC shows a rather sparse
distribution when computed on two scans only (with a wide range of positive and nega-
tive values), a behaviour which is reduced in the 3 scans analysis. In all the 16 subjects
with at least three repeated scans the ELBA score increased, showing the sensitivity of
the method to amyloid deposition even in a relatively short time span (48 months) and
opening potential applications to pharmacological studies with anti-amyloid compounds.
Even taking into account the relatively strong uncertainty due to the use of only two scans,
ASC values peaked in the EMCI cohort, are mildly positive within normal subjects and
are substantially compatible with zero in AD, a behaviour which is expected according to
the latest models of amyloid load (Jack et al., 2013).
The comparison between ELBA ASC and CSF Aβ42 points to a discrete, inverse relation
between CSF Aβ42 level and variations in brain amyloid load, taking into account that
they reflect indirect measures of a biologically complex phenomenon.
According to our results which focused on patients with a negative or borderline positive
ELBA score at baseline, brain amyloid accumulation appears to be faster in those with a
pathological low CSF Aβ42 levels, in line with current knowledge.
The relatively high scattering of ASC value of both ELBA and SUVr scores tells us
that we are still rather far from being able to use differential measures at the single
subject level. This limitation alone should sponsor new methodological approaches to
semi-quantification on amyloid-PET images.
Compared to longitudinal SUVr values though, ELBA shows lesser variability. This is
likely due to the fact that reference (and uptake) region is not needed, the selection of
which has recently been shown to impair the reproducibility and accuracy of longitudinal
SUVr measurements (Landau et al., 2015).
In addition, the average ASC values found in our work are comparable to those proposed
by (Jack et al., 2013) using SUVr measurements, suggesting that the important clinical
and pharmacological implications of an accurate longitudinal evaluation at the cohort
level are within our reach, particularly if the protocol involves three or more PET scans.
The high uncertainty in the longitudinal analysis – hence the presence of a significant
number of subjects with negative amyloid trend – is mostly due to a measurement /
methodological noise rather than a real variation in the data. Indeed, in the cohort
subset with three scans, this phenomenon is greatly attenuated.
In the matter of measurement uncertainty (or equivalently the test-retest error) which
impairs the typical 2-points longitudinal study, we attempted the cross-sectional estima-
tion. While this is not a true test-retest measure, we can at least rank the three methods
on the base of their variances on a common, homogeneous population.
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Results in paragraph 8.3 show that TDr is indeed the most reliable of the three measures
and suggest that it could have a decidedly lower error in a proper longitudinal study.
The cross-sectional approach relies on several assumptions which are not always satisfied.
For instance, the distribution of the standard deviation is not always independent on the
cohort. In addition, many more subjects should be included so that we can vary the clus-
tering parameters and provide proper homogeneous cohorts (for instance by optimizing
on the degree of order). We should then verify that the results are independent from the
number of clusters. In our study we tried 3 to 8 clusters, although we limited the results
to 3 because of the optimal balance of the cohort sizes.
Even with all these limitations, we are still confident that TDr ir perhaps the most robust
of all three methods.
11.4 Regional analysis
Another open area of investigation is the brain ROI specialization. In this work we
considered the brain parcellation to be a pre-defined atlas with 50 cortical regions (25
per hemisphere), with the intent to describe the complexity of amyloid accumulation and
have a more stable final result.
Results however indicate that the relationship between uptake regions and method is not
so straightforward and each method might perform best on its own regions (figure 8.6).
For instance, ELBA was developed in order to overcome the weaknesses inherent to the
SUVr computation, and for this reason the method is not suitable to be applied on small
ROIs such as those used in SUVr analysis (see figure 8.3).
In facts, ELBA performance on the strictly defined atlas regions was rather poor, and
this problem was solved by extending each uptake region (figure 8.4). Still, ELBA could
probably work best when specialized on brain macro regions such as the frontal or parietal
lobes.
Another area of investigation is the conciliation between fixed uptake ROIs (like those
found in SUVr and TDr) with arbitrary parcellation regions – in principle – which might
divide, partially overlap of skip them entirely. In this work we used a probability map
to be used as local weights for SUVr, so that it could be computed regardless of the
parcellation. This solution however might have impaired the regional performance and
further studies are needed to look for possible extensions of SUVr when dealing with an
externally imposed parcellation (figure 8.3 and 8.6).
On the same note, TDr was left with its own ROIs as we found them to be rather dense
on the cortical areas. Therefore we assumed that each parcellation region would include
at least one TDr ROI. This assumption however was not thoroughly verified and there
is no guarantee that performance is not impaired on regions with unbalanced number of
uptake ROIs.
A possible solution to all these problems is under study. We are currently investigating
an adaptive atlas (macro-parcellation) that take into consideration each method’s uptake
ROIs, while preserving the latitude needed for ELBA to be properly applied.
The macro-parcellation approach should be investigated more as alternative for all fixed
parcellations, as it could also prove easier to integrate into the human experience in the
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process of clinical assessment.
11.5 Ranking
During our tests the clinicians feedback on the rank were very positive. Indeed, from
the mathematical point of view we know the rank to be a better choice than any single
measure. If a set of independent measures have uncertainties that are of the same order
of magnitude, combining them has always been the method of choice for delivering more
robust results (the standard deviation on the mean of n measurements is σ/√n).
There still is the open question whether the ordering on the first component of the PCA
applied to the quantile-normalized measure matrix is the best choice. One criteria is that
it shows the least degree of order statistics (figure 9.8).
The presence of a transition in cerebral amyloidosis is known from many studies (Chin-
carini et al., 2012; Burgold et al., 2014) and has motivated us to use the degree of order
as sensor to gauge subgroups coherence as the accumulation process progresses.
We defined the state vector of the system as the ensemble of the regional and global
quantifiers on all three methods. The DO was built by exploiting the PCA, as the fraction
of variance expressed by the first component with respect to all the others. This approach
is a variant of similar definitions found in literature (Gorban et al., 2010; Pagani et al.,
2016).
Unlike the work of Pagani et al. (2016) – whose cohorts were provided by an external
evaluation of the cognitive state – in our analysis the cohorts were data driven (i.e.
generated by a moving subset on the ordered values of the first PCA).
The approach of the DO of the system is allowed assuming the validity of the ergodic
hypothesis, as discussed in Pagani et al. (2016). The dynamics of a system is considered
ergodic if it has the same behavior when averaged over time or averaged over the space
of all the states of the system (phase space). In our case, that amounts to assume that
the average of the amyloid accumulation process over time and that of the statistical
(sub)set are the same. In other words, that implies that the ranked subject are actually
a realization of the accumulation process, lying on the mean trajectory from negativity
to positivity.
If the ergodic hypothesis is satisfied, the degree of order that was measured among patients
of the same class will give the same result as that shown by the other patient at different
times, if they are within the interval where we can safely assume the invariance of the
clinical status.
In retrospective, the ranking using the first PCA component was expected to be the
best ranking according to the DO variance. In facts, this is true if the only relevant
information is the amyloid load and if this information is completely explained by the
fist component only. Then, by the definition of the DO (equation 9.5) all other variances do
not carry information, i.e. they only encode noise (the physiological variability). This was
actually verified by showing that the other PCA components on the quantile-normalized
matrix (up to the fifth) did not carry any information in terms of amyloid load (AUC
≈ 0.5).
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11.6 Study limitations
An unavoidable limitation of this study is the lack of a true gold standard (i.e. neuritic
plaques at autopsy) that can be used to evaluate the accuracy of the imaging quantitation,
and to set an absolute threshold for positivity. Unfortunately there are relatively few
examples of such cases in literature (see for instance Clark et al. (2012) or Sabri et al.
(2015)). As practical solution – also shown by Johnson et al. (2013a) – we used the
consensus visual read as the reference standard, together with the CSF Aβ42 and SUVr
measurements when available.
In practice, the cross-comparison of all methods should provide the ground for a reasonable
method validation targeted at the clinical practice.
Because of the peculiar image treatment which evaluates the intensity distribution pat-
terns, the main drawback for the ELBA analysis is the image quality and consistency. A
similar remark can be made on TDr, where the small size and scattered spatial distribution
of the uptake regions can be prone to large measure uncertainty in noisy images.
Although convincing evidence can be drawn even from multi-centric and blind analysis
such as this one, the weight of the acquisition-related variables can be significant. To
correctly estimate this effect we are planning a more detailed analysis on images coming
from a single center but with different acquisition protocols and image reconstruction
parameters.
Finally, each method has its own strength and weakness. For instance, the ELBA method
mimics the visual process in that it captures global geometrical and intensity features,
and it is therefore reasonably correlated to the reader’s assessment. TDr and SUVr both
rely on intensity ratios but based on fundamentally different approaches. It is therefore
possible that we can find cases where one method excels and others fail. This is why we
believe that any usefulness in a clinical setting is likely to be most informative if we use
all of them combined.
Chapter 12
Conclusion
Future diagnostic pathways to the early assessment of neurodegenerative diseases will
strongly rely on the in-vivo measurement of cerebral amyloid load.
To date, amyloid-PET ranks among the most reliable and less invasive technique available
to clinicians. Yet, the relative novelty of amyloid tracers and the challenges in proper
quantification are still an obstacle to all but the most experienced and qualified research
centers.
The goal of quantification in amyloid-PET is to extract reliable measures to describe the
progress of of accumulation of cerebral Aβ. Some implementation of the quantification
process (i.e. those that go under the name of semi-quantification) are widely applicable
and prone to the development of automatic analysis.
At present, semi-quantitative analysis is carried out with the SUVr procedure (and its
variants), generally calculated on entire brain volume. SUVr has several limitations,
which prompted us to look for alternative methods and independent approaches.
We have developed and validated two additional novel semi-quantification methods:
ELBA (Chincarini et al., 2016) and TDr (paper under preparation). The three methods
(SUVr, ELBA and TDr) are all independent as they are based on fundamentally different
approaches. Yet they investigate the uptake of the tracer so that each provides a proxy
measure of the cerebral amyloid load. The benefit of independent methods is that their
errors are uncorrelated and they have possibly different sensitivities to various nuisances
such as the presence of atrophic regions, the image reconstruction parameters and the
presence of noise.
A further and consequential step was to integrate all possible measures into a single
quantifier. We have researched in this topic and developed a simple and robust quantifier
from the whole set of measures and methods. In doing this, we eviscerated the information
present in the PET scans, both in terms of local and whole-brain quantitation and in terms
of clinical and longitudinal relationships.
Finally, we implemented all the analyses into an easy-to-use web service, which registered
Nuclear Medicine and Neurological departments can access, and exploit the detailed in-
formation we packed into the report.
Both scientific results and direct feedback from the clinical departments are very encour-
aging. We have demonstrated that an alternative approach to quantification is possible,
one that evolves the current binary assessment into a proper continuous scale and that,
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at the same time, provides fundamental and complementary information to the clinical
evaluation.
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